var title_f23_25_23952="ECD x-ray";
var content_f23_25_23952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Osteosclerosis and osteolysis in Erdheim-Chester disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    X-ray of left femur revealed diffuse osteosclerosis with focal osteolysis in the diaphysis and metaphysis of the left distal femur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kim MS, Kim CH, Choi SJ, et al. Erdheim-Chester disease. Ann Dermatol 2010; 22:439. Copyright &copy; 2010 Korean Dermatological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23952=[""].join("\n");
var outline_f23_25_23952=null;
var title_f23_25_23953="Patient information: Paronychia (The Basics)";
var content_f23_25_23953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82907\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/57/39834\">",
"         Paronychia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/1/42001\">",
"         Patient information: Fungal nail infections (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Paronychia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/paronychia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25818072\">",
"      <span class=\"h1\">",
"       What is paronychia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Paronychia is a skin infection that happens around the fingernails or toenails (",
"      <a class=\"graphic graphic_picture graphicRef82767 \" href=\"UTD.htm?38/57/39834\">",
"       picture 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      You are more likely to get to get this infection if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Push down or trim the skin at the base of the nail (called the &ldquo;cuticle&rdquo;).",
"       </li>",
"       <li>",
"        Bite your nails.",
"       </li>",
"       <li>",
"        Suck your thumb or finger.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have jobs that make them keep their hands in water a lot are also more likely to get paronychia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25818087\">",
"      <span class=\"h1\">",
"       What are the symptoms of paronychia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A painful, red, swollen area around the nail",
"       </li>",
"       <li>",
"        Pus-filled blisters near the nail",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25818102\">",
"      <span class=\"h1\">",
"       Is there a test for paronychia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25818117\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some people feel better if they:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Soak the affected finger or toe in warm water for 20 minutes, 3 times a day.",
"       </li>",
"       <li>",
"        Put antibiotic cream such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?5/63/6132?source=see_link\">",
"         mupirocin",
"        </a>",
"        (brand name: Bactroban Cream&reg;) on the infected area after soaking it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25818132\">",
"      <span class=\"h1\">",
"       How is paronychia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the treatments you have tried on your own don&rsquo;t help, your doctor might give you antibiotics to treat the infection.",
"     </p>",
"     <p>",
"      If you have a pus-filled blister, he or she might give you a shot to numb your finger or toe and use a needle or sharp tool to open and drain the blister. You will need to soak your finger or toe and take antibiotics after this procedure.",
"     </p>",
"     <p>",
"      Your doctor might also prescribe other medicines, such as steroids or anti-fungal medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25818147\">",
"      <span class=\"h1\">",
"       Can paronychia be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting paronychia if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Push your cuticles down gently and do not trim or cut them.",
"       </li>",
"       <li>",
"        Wear rubber gloves if you need to put your hands in water.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25818162\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/1/42001?source=see_link\">",
"       Patient information: Fungal nail infections (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/25/23953?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82907 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23953=[""].join("\n");
var outline_f23_25_23953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25818072\">",
"      What is paronychia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25818087\">",
"      What are the symptoms of paronychia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25818102\">",
"      Is there a test for paronychia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25818117\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25818132\">",
"      How is paronychia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25818147\">",
"      Can paronychia be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25818162\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82907\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/57/39834\">",
"      Paronychia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/1/42001?source=related_link\">",
"      Patient information: Fungal nail infections (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_25_23954="US appendicitis in pregnancy1";
var content_f23_25_23954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53123%7EOBGYN%2F58749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53123%7EOBGYN%2F58749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sonogram of appendicitis in pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 207px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonogram of the right lower quadrant in a woman with appendicitis who is 6 weeks pregnant. Note the markedly thick-walled appendix (calipers) measuring 16 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sonogram of appendicitis in pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonogram of the right lower quadrant in a woman with appendicitis at 21 weeks of gestation. Note the fluid-filled appendix with appendicoliths (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23954=[""].join("\n");
var outline_f23_25_23954=null;
var title_f23_25_23955="Megaloblastic erythropoiesis";
var content_f23_25_23955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Megaloblastic erythropoiesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of normal and megaloblastic erythropoiesis with respect to erythroid precursors in the bone marrow. Left panel: Normal erythropoiesis. Right panel: Megaloblastic erythropoiesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23955=[""].join("\n");
var outline_f23_25_23955=null;
var title_f23_25_23956="Oxymetazoline (nasal): Patient drug information";
var content_f23_25_23956=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxymetazoline (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/14/13541?source=see_link\">",
"     see \"Oxymetazoline (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22340?source=see_link\">",
"     see \"Oxymetazoline (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      12 Hour Nasal Relief [OTC];",
"     </li>",
"     <li>",
"      4-Way&reg; 12 Hour [OTC];",
"     </li>",
"     <li>",
"      Afrin&reg; Extra Moisturizing [OTC];",
"     </li>",
"     <li>",
"      Afrin&reg; Original [OTC];",
"     </li>",
"     <li>",
"      Afrin&reg; Severe Congestion [OTC];",
"     </li>",
"     <li>",
"      Afrin&reg; Sinus [OTC];",
"     </li>",
"     <li>",
"      Dristan&reg; [OTC];",
"     </li>",
"     <li>",
"      Duramist Plus [OTC];",
"     </li>",
"     <li>",
"      Neo-Synephrine&reg; Nighttime12-Hour [OTC];",
"     </li>",
"     <li>",
"      Nostrilla&reg; [OTC];",
"     </li>",
"     <li>",
"      NRS&reg; [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Sinex&reg; VapoSpray 12-Hour;",
"     </li>",
"     <li>",
"      Vicks&reg; Sinex&reg; VapoSpray 12-Hour UltraFine Mist [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Sinex&reg; VapoSpray Moisturizing 12-Hour UltraFine Mist [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9504216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Claritin&reg; Allergic Decongestant;",
"     </li>",
"     <li>",
"      Dristan&reg; Long Lasting Nasal;",
"     </li>",
"     <li>",
"      Drixoral&reg; Nasal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702660",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxymetazoline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use for more than 3 days. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12276 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23956=[""].join("\n");
var outline_f23_25_23956=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504215\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504216\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024439\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024441\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024440\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024445\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024446\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024448\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024443\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024444\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024449\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024450\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/14/13541?source=related_link\">",
"      Oxymetazoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22340?source=related_link\">",
"      Oxymetazoline (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/46/9955?source=related_link\">",
"      Oxymetazoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/0/2052?source=related_link\">",
"      Oxymetazoline (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32386?source=related_link\">",
"      Oxymetazoline (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_25_23957="Diphenhydramine and phenylephrine: Patient drug information";
var content_f23_25_23957=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diphenhydramine and phenylephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/24/8582?source=see_link\">",
"     see \"Diphenhydramine and phenylephrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6803585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldex&reg; CT;",
"     </li>",
"     <li>",
"      Benadryl-D&reg; Allergy &amp; Sinus [OTC];",
"     </li>",
"     <li>",
"      Benadryl-D&reg; Children's Allergy &amp; Sinus [OTC];",
"     </li>",
"     <li>",
"      Dimetapp&reg; Children&rsquo;s Nighttime Cold &amp; Congestion [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Night Time Cold &amp; Cough [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701960",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diphenhydramine, phenylephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension, syrup) if you cannot swallow pills. Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12167 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23957=[""].join("\n");
var outline_f23_25_23957=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803585\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021070\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021072\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021071\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021076\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021077\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021079\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021074\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021075\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021080\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021081\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/24/8582?source=related_link\">",
"      Diphenhydramine and phenylephrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_25_23958="Treatment of amyloid cardiomyopathy";
var content_f23_25_23958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of amyloid cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23958/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23958/contributors\">",
"     Rodney H Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23958/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23958/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23958/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23958/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23958/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/25/23958/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17201746\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis refers to the extracellular deposition of fibrils that are composed of low molecular weight subunits (5 to 25 kD) of a variety of serum proteins. These fibrils adopt a beta-pleated sheet configuration that leads to characteristic histologic changes. Amyloid deposits can occur in a variety of organs, with involvement of the heart, kidney, liver, and autonomic nervous system most often being responsible for morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of cardiac involvement varies among types of amyloidosis. The prognosis of amyloid cardiomyopathy also varies among types of amyloidosis, with high mortality rates particularly in light&ndash;chain (AL) amyloidosis.",
"   </p>",
"   <p>",
"    This topic will review the treatment of amyloid cardiomyopathy. The clinical manifestations and diagnosis of amyloid cardiomyopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788149\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17968625\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of symptomatic cardiac amyloidosis is twofold: therapy of heart failure and treatment of the underlying disease. Patients with TTR amyloidosis generally respond better to heart failure therapy than patients with AL amyloidosis. However, there are more therapeutic options for addressing the underlying disease in AL amyloidosis, and if the plasma cell dyscrasia can be controlled, there is often a relatively rapid decrease in serum biomarkers of heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788156\">",
"    <span class=\"h2\">",
"     Heart failure therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17203130\">",
"    <span class=\"h3\">",
"     Approach to heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of heart failure in patients with cardiac amyloidosis differs from the therapy generally recommended in patients with diastolic or systolic heart failure. While loop diuretics are a mainstay of treatment of cardiac amyloidosis, beta-blockers and ACE inhibitors may be harmful despite their efficacy in other types of systolic heart failure. Similarly, calcium channel blockers that may be useful in treatment of diastolic heart failure are contraindicated in amyloid cardiomyopathy. Adverse responses to drugs in cardiac amyloidosis are likely due to its unique pathophysiologic features.",
"   </p>",
"   <p>",
"    Heart failure in cardiac amyloidosis is due to a combination of decreased myocardial compliance and disrupted and compressed myocardial cells, caused by physical infiltration of amyloid deposits. In addition, there is experimental evidence that excessive circulating free light chains in AL amyloidosis are cardiotoxic, possibly explaining the worse prognosis in cardiac AL amyloidosis than TTR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link&amp;anchor=H165325929#H165325929\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\", section on 'Types of amyloidosis that may involve the heart'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathological changes that result from extensive amyloid infiltration result in a non-dilated normal to small left ventricular cavity size, with impaired filling because of decreased compliance. In late-stage disease, the left ventricular ejection fraction is reduced without the ability of the LV to undergo compensatory dilation as it does in most other cardiac diseases. In addition, the infiltration of the atria may severely impair atrial contraction, further decreasing ventricular filling. This combination results in a decreased stroke volume and cardiac output and marked elevation of intracardiac pressures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15688389\">",
"    <span class=\"h3\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop diuretics are a mainstay of the management of heart failure. If edema is severe, hospitalization and a course of intravenous diuretics should be strongly considered. This should be accompanied by careful monitoring of blood pressure and renal function, as overvigorous diuresis may result in progressive azotemia. Aldosterone antagonist therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ) in conjunction with loop diuretics is generally tolerated without the development of excessive hypotension.",
"   </p>",
"   <p>",
"    Although beta blockers reduce morbidity and mortality in patients with systolic heart failure generally, they have no proven benefit in patients with heart failure due to cardiac amyloidosis. Indeed, they may worsen heart failure in patients with cardiac amyloidosis in whom cardiac output is dependent on heart rate due to presence of a low, fixed stroke volume.",
"   </p>",
"   <p>",
"    The safety and efficacy of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with cardiac amyloidosis is uncertain. There are no clinical trials of ACE inhibitors or ARBs in amyloidosis, but clinical experience has shown that these agents often provoke profound hypotension in AL amyloidosis, possibly by exposing a subclinical autonomic neuropathy. ACE inhibitors and ARBs appear to be better tolerated in patients with senile cardiac amyloidosis, in whom autonomic neuropathy is rare. Tolerability of ACE inhibitors and ARBs in TTR cardiomyopathy due to a mutant protein depends on the presence or absence of concomitant neuropathic features. If a trial of ACE inhibition is attempted in a patient with AL amyloidosis, initiation should be with a very low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    (eg, 3.125 mg) with careful blood pressure monitoring and slow, carefully monitored up-titration of the dose if tolerated. &nbsp;",
"   </p>",
"   <p>",
"    Amyloid fibrils bind to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and this interaction may account for increased susceptibility to digitalis toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium channel blockers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    that are used to slow heart rate and that may possibly improve ventricular relaxation in diastolic heart failure (eg, in hypertensive heart disease or hypertrophic cardiomyopathy) are ineffective in cardiac amyloidosis, as the diastolic dysfunction is due to the amyloid and not to myocardial cellular dysfunction. Indeed, these drugs are contraindicated, as their negative inotropic effects may be profound, possibly because of an abnormal binding to amyloid fibrils and may depress compensatory heart rate responses to low stroke volume and cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15688512\">",
"    <span class=\"h3\">",
"     Heart transplantation and ventricular assist devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The great majority of patients with cardiac AL amyloidosis have significant noncardiac amyloidosis and are not suitable candidates for heart transplantation. For example, in one series, only 4 percent of patients had clinically isolated cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with senile systemic amyloidosis generally have the disease clinically isolated to the heart and as such would appear to be more suitable candidates. However, most patients are diagnosed in their eighth decade of life and are excluded based on their age. Nevertheless, successful heart transplantation has been carried out in a few patients with SSA who presented at a younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early experience with cardiac transplantation in AL amyloidosis did not address the underlying plasma cell dyscrasia and, not surprisingly, the disease progressed in other organs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    returned in the transplanted heart [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The few major centers that accept patients with AL amyloidosis for cardiac transplantation accept only those who have disease clinically isolated to the heart and are deemed to be at too great a risk from the intensive chemotherapy required for hematopoietic cell transplantation (HCT). Heart transplantation for AL amyloidosis needs to be followed by high&ndash;dose chemotherapy and autologous HCT within a 12-month period. Long-term follow-up data in these patients are not yet available, but several appear to have had excellent cardiac results and a durable hematologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ventricular assist devices have been used very infrequently in cardiac amyloidosis, owing to technical difficulties when used in a restrictive cardiomyopathy as well as the presence of co-existing noncardiac amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/12\">",
"     12",
"    </a>",
"    ]. A case of the use of total artificial heart as a bridge to transplantation in a patient with senile systemic amyloidosis has been reported, with survival for several months while the patient awaited heart transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17203159\">",
"    <span class=\"h2\">",
"     Treatment of atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If atrial fibrillation with a rapid ventricular response develops in a patient with AL or TTR amyloidosis, low-dose beta-blockade and careful",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    use may help with rate control (notwithstanding the above concerns about beta-blocker and digoxin use in amyloid cardiomyopathy generally). Despite severely impaired atrial contractile function, clinical improvement may occur after restoration of sinus rhythm in a patient with atrial fibrillation of recent onset, possibly due to a regularization of the heart rate.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    use to maintain sinus rhythm appears to be well-tolerated without specific amyloidosis-related side-effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link\">",
"     \"Management of new onset atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788164\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid cardiomyopathy is associated with high risk of intracardiac thrombus, predominantly in the atria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link&amp;anchor=H2726709#H2726709\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\", section on 'Thromboembolism and stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticoagulation is indicated if a patient with amyloid develops atrial fibrillation, since the risk of intracardiac thrombus is very high. The CHADS2 score for assessing stroke risk in atrial fibrillation is not of value in cardiac amyloidosis, and all patients should be considered at very high risk regardless of the absence of a high CHADS2 score. &nbsp;",
"   </p>",
"   <p>",
"    Although the role of anticoagulation in patients in sinus rhythm is uncertain, we suggest anticoagulation in patients in sinus rhythm with either a diminutive transmitral A wave or depressed left atrial appendage velocity on transesophageal echo, particularly if AL type is present. Atrial failure, even in the presence of sinus rhythm, is very common in amyloidosis and is associated with atrial thrombus formation, particularly in patients with AL type [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although amyloidosis is associated with increased hemorrhagic risk due to amyloid angiopathy, intestinal or bladder amyloid, or coagulopathy, major bleeding in anticoagulated patients does not seem to exceed that seen in other patients with similar non-amyloid degrees of illness, so anticoagulation should not be withheld if indicated unless a clear-cut contraindication exists. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788171\">",
"    <span class=\"h2\">",
"     Implantable cardioverter-defibrillator",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of implantable cardioverter-defibrillator (ICD) therapy in patients with cardiac amyloidosis is uncertain. Sudden cardiac death (SCD) is common in patients with cardiac AL amyloidosis and prophylactic implantable cardioverter-defibrillators (ICDs) have been suggested as an option to reduce this risk. However, electromechanical dissociation appears to be a significant cause of SCD in these patients, so the role of ICD therapy in preventing SCD in this population is unclear.",
"   </p>",
"   <p>",
"    This issue was illustrated by a study in which 19 cardiac AL amyloidosis patients with history of syncope (n = 4) or high-grade ventricular arrhythmias (n = 10), or both (n = 5) received an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/15\">",
"     15",
"    </a>",
"    ]. Two subsequently underwent cardiac transplant and one died of an unrelated disease. There were six cardiac deaths, all sudden despite the ICD. One patient received appropriate shocks but later died of electromechanical dissociation, which was also the cause of death in the other five. Only one patient received appropriate ICD shocks with long-term survival.",
"   </p>",
"   <p>",
"    Thus, the limited available clinical data do not support use of ICDs for primary prevention of sudden cardiac death in patients with cardiac amyloidosis of any etiology. In the rare patient with cardiac amyloidosis who is resuscitated from a life-threatening ventricular arrhythmia, implantation of an ICD is appropriate. However, even in these cases, it offers less effective protection than in other forms of heart disease, as electromechanical dissociation can occur, either as primary terminal event or following an appropriate ICD shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788185\">",
"    <span class=\"h1\">",
"     TREATMENT OF THE UNDERLYING PROTEIN MISFOLDING DISORDER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788192\">",
"    <span class=\"h2\">",
"     Specific therapy for AL amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed in detail separately, survival in patients with AL amyloidosis varies with the extent of organ involvement and median survival is as short as four to six months in those with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link&amp;anchor=H863317#H863317\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\", section on 'Prognosis'",
"    </a>",
"    .) However, with earlier diagnosis, careful patient selection, and use of currently available chemotherapeutic regimens, survival can be significantly prolonged. The available medical regimens are discussed separately, but the basic principles will be reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, therapy involves the administration of chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autologous stem cell transplantation (ASCT) in an attempt to eradicate the underlying plasma cell clone responsible for AL amyloid formation. The goal of therapy is to achieve a 90 percent or greater reduction in serum free light chain levels, but not all patients may be able to attain this level of response. The intensity and type of therapy chosen is affected by the number and extent of organ involvement. The most common chemotherapy regimens used include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based regimens such as bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and dexamethasone. ASCT involves administration of high-dose melphalan followed by stem cell rescue. The risk of treatment-related mortality associated with ASCT in AL amyloidosis restricts the use of this procedure to a small group of selected patients. NYHA functional class III or IV heart failure is generally considered a contraindication to ASCT in patients with AL amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788234\">",
"    <span class=\"h2\">",
"     Specific therapy of TTR amyloidosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788241\">",
"    <span class=\"h3\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In ATTR amyloidosis, the source of the amyloidogenic protein is the liver. Transplantation of the liver removes the mutant amyloidogenic TTR in familial ATTR but in senile systemic amyloidosis the precursor protein is native TTR and thus liver transplantation is not indicated. Unfortunately, cardiac disease has progressed after liver transplantation in some patients with familial ATTR, even though deposits elsewhere may stabilize. [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/16\">",
"     16",
"    </a>",
"    ]. Examination of the composition of TTR in the heart of patients with progressive cardiomyopathy after liver transplantation reveals that the mechanism is enhanced deposition of wild-type TTR on a template of amyloid derived from variant TTR. Patients with advanced heart disease may be treated with combined heart and liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once a patient with a transthyretin mutation is found to have a positive biopsy for amyloid, he or she should undergo evaluation for liver transplantation, with the goal to receive the transplant as early in the disease as possible. If an amyloid cardiomyopathy is present with significant heart failure, isolated liver transplantation is contraindicated and consideration should be given to a combined liver-heart transplant or just heart alone. This appears to be particularly true in patients with the Ala60 mutation in whom cardiomyopathy is almost always present and in whom liver transplant alone does not stop progressive cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/18\">",
"     18",
"    </a>",
"    ] . &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788248\">",
"    <span class=\"h2\">",
"     Investigational agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several investigational agents are in active trials. Agents targeting TTR may prove beneficial for wild-type (senile) as well as familial ATTR amyloidosis. These include tafamidis, a drug that stabilizes the TTR molecule, thereby hopefully decreasing the breakdown products that form amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23958/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. It has been approved in most European countries for the treatment of early amyloid polyneuropathy due to familial amyloidosis, but there have been no placebo-controlled trials in TTR cardiac amyloidosis. Drugs that decrease the liver production of transthyretin, resulting in a significant decrease in the circulating levels of transthyretin, are also entering clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16788255\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of symptomatic cardiac amyloidosis is twofold: therapy of heart failure and treatment of the underlying disease. (See",
"      <a class=\"local\" href=\"#H17968625\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of heart failure in patients with cardiac amyloidosis differs from the therapy generally recommended in patients with diastolic or systolic heart failure. While loop diuretics are a mainstay of treatment of cardiac amyloidosis, beta blockers and ACE inhibitors are often not tolerated despite their efficacy in other types of systolic heart failure. Similarly, calcium channel blockers that may be useful in treatment of diastolic heart failure are contraindicated in amyloid cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H16788156\">",
"       'Heart failure therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticoagulation is recommended in patients with amyloid cardiomyopathy with atrial fibrillation, intracardiac thrombi, or an embolic event. In addition, we suggest anticoagulation in patients in sinus rhythm who have evidence of atrial contractile dysfunction. (See",
"      <a class=\"local\" href=\"#H16788164\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of implantable cardioverter-defibrillator therapy in patients with severe cardiac amyloidosis appears to be limited. (See",
"      <a class=\"local\" href=\"#H16788171\">",
"       'Implantable cardioverter-defibrillator'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main treatment option in patients with AL amyloidosis is chemotherapy. A variety of regimens are now used, including high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      with autologous hematopoietic stem cell transplantation (HCT).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      -based regimens are becoming first line therapy, even in patients with advanced cardiac disease (New York Heart Association functional class III or IV) (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16788192\">",
"       'Specific therapy for AL amyloidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transplantation of the liver can be curative in selected patients with familial ATTR but not in senile systemic amyloidosis. However, cardiac disease has progressed after liver transplantation in some patients with familial ATTR. Patients with advanced heart disease with familial ATTR may be treated with combined heart and liver transplantation. (See",
"      <a class=\"local\" href=\"#H16788234\">",
"       'Specific therapy of TTR amyloidosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/1\">",
"      Griffiths BE, Hughes P, Dowdle R, Stephens MR. Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax 1982; 37:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/2\">",
"      Gertz MA, Skinner M, Connors LH, et al. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 1985; 55:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/3\">",
"      Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993; 104:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/4\">",
"      Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/5\">",
"      Fuchs U, Zittermann A, Suhr O, et al. Heart transplantation in a 68-year-old patient with senile systemic amyloidosis. Am J Transplant 2005; 5:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/6\">",
"      Dubrey S, Simms RW, Skinner M, Falk RH. Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival. Am J Cardiol 1995; 76:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/7\">",
"      Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 1991; 84:III338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/8\">",
"      Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005; 24:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/9\">",
"      Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004; 23:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/10\">",
"      Pelosi F Jr, Capehart J, Roberts WC. Effectiveness of cardiac transplantation for primary (AL) cardiac amyloidosis. Am J Cardiol 1997; 79:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/11\">",
"      Maurer MS, Raina A, Hesdorffer C, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 2007; 83:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/12\">",
"      Frazier OH, Cohn WE. Continuous-flow total heart replacement device implanted in a 55-year-old man with end-stage heart failure and severe amyloidosis. Tex Heart Inst J 2012; 39:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/13\">",
"      Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007; 116:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/14\">",
"      Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009; 119:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/15\">",
"      Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/16\">",
"      Dubrey SW, Davidoff R, Skinner M, et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997; 64:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/17\">",
"      Raichlin E, Daly RC, Rosen CB, et al. Combined heart and liver transplantation: a single-center experience. Transplantation 2009; 88:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/18\">",
"      Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012; 33:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/19\">",
"      Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 2012; 109:9629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23958/abstract/20\">",
"      Said G, Grippon S, Kirkpatrick P. Tafamidis. Nat Rev Drug Discov 2012; 11:185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85952 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23958=[""].join("\n");
var outline_f23_25_23958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16788255\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17201746\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16788149\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17968625\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16788156\">",
"      Heart failure therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17203130\">",
"      - Approach to heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15688389\">",
"      - Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15688512\">",
"      - Heart transplantation and ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17203159\">",
"      Treatment of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16788164\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16788171\">",
"      Implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16788185\">",
"      TREATMENT OF THE UNDERLYING PROTEIN MISFOLDING DISORDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16788192\">",
"      Specific therapy for AL amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16788234\">",
"      Specific therapy of TTR amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16788241\">",
"      - Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16788248\">",
"      Investigational agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16788255\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/85952\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/85952|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=related_link\">",
"      Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_25_23959="Post-ERCP septic complications";
var content_f23_25_23959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-ERCP septic complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23959/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23959/contributors\">",
"     Silvano Loperfido, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23959/contributors\">",
"     Guido Costamagna, MD, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23959/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23959/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23959/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23959/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/25/23959/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is one of the most morbid complications of endoscopic retrograde cholangiopancreatography (ERCP) and among the most common causes of ERCP-related death. Septic complications of ERCP include ascending cholangitis, liver abscess, acute cholecystitis, infected pancreatic pseudocyst, infection following perforation of a viscus, and less commonly,",
"    <span class=\"nowrap\">",
"     endocarditis/endovasculitis.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    post-ERCP septic complications of acute cholangitis, acute cholecystitis, and pancreatic sepsis will be reviewed here. Post-ERCP perforation and general overviews of acute cholangitis and acute cholecystitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20072?source=see_link\">",
"     \"Post-ERCP perforation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteria can enter the biliary tract by either a hematogenous or, more frequently, a retrograde route. In patients with a normal biliary tract, anatomical barriers impede both these routes. In contrast, patients who are immunocompromised or who have obstruction of the biliary system have impaired bacterial defenses, making them more susceptible to these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequent organisms responsible for post-ERCP infections are enteric bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Although polymicrobial enteric flora are often found in infected bile, single organisms are isolated from blood cultures in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/1\">",
"     1",
"    </a>",
"    ]. In the 1980s, cross infection via contaminated endoscopes and ancillary ERCP equipment, such as cannulation catheters, was implicated in severe cases or outbreaks of septicemia from pseudomonas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Improvements in the methods of disinfection have now made such nosocomial infections rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PERIPROCEDURAL BACTEREMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both diagnostic and therapeutic ERCP can lead to transient bacteremia that, in most cases, is not clinically significant. Variable rates of up to 15 percent have been reported for diagnostic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and of up to 27 percent for therapeutic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/7,9-11\">",
"     7,9-11",
"    </a>",
"    ]. Differences in specimen collection, timing of blood cultures, and culture techniques may explain the variable estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacteria isolated from the blood following ERCP are commonly oropharyngeal flora, particularly alpha-hemolytic streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Entrance into the blood stream is presumably through minor trauma by the endoscope, similar to bacteremia that has been observed with tooth brushing or after diagnostic upper gastrointestinal endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic periprocedural bacteremia rarely leads to clinical sepsis in immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/9\">",
"     9",
"    </a>",
"    ]. As a result, bacteremic episodes occurring during ERCP do not appear to have clinically significant consequences. Antibiotic prophylaxis is not warranted in most patients. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Antibiotic prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASCENDING CHOLANGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascending cholangitis, while uncommon, is the most frequent infectious complication of ERCP. Clinical manifestations include fever, jaundice, and abdominal pain that result from stasis and infection in the biliary tract. In the setting of ERCP, it is most often due to incomplete drainage of an infected and obstructed biliary system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the incidence of clinically significant cholangitis have ranged from 0.4 to more than 10 percent in various reports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/1,2,14-17\">",
"     1,2,14-17",
"    </a>",
"    ]. In a summary of 21 prospective studies involving 16,855 patients between 1987 and 2003, infection occurred in 1.4 percent (0.2 percent were severe), with a periprocedural mortality rate of 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/14\">",
"     14",
"    </a>",
"    ]. Similar rates of infection (1.0 to 2.2 percent) were reported in other large studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/2,15,16\">",
"     2,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors for cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to achieve drainage of an obstructed biliary system is the most important predictor of post-ERCP biliary sepsis. The mechanism by which obstruction leads to sepsis is presumed to be elevated biliary pressure causing biliary-venous reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of cholangitis varies depending upon the nature and site of the obstruction. Patients with malignant hilar obstructions and those with sclerosing cholangitis are at particularly increased risk of cholangitis due to difficulty in achieving complete drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/5,18-24\">",
"     5,18-24",
"    </a>",
"    ]. Cholangitis is also a frequent complication of occluded biliary stents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of incomplete drainage as a risk factor for cholangitis was illustrated in two retrospective series in which incomplete biliary drainage was present in 87 and 90 percent of patients who developed sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. High rates of cholangitis in patients with incomplete biliary drainage were also found in a prospective study of 242 patients undergoing sphincterotomy for bile duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/26\">",
"     26",
"    </a>",
"    ]. Cholangitis developed in 75 percent of patients with retained stones and failed biliary drainage and in 40 percent of those with a precut papillotomy and unsuccessful drainage. By comparison, cholangitis developed in only 3 percent of patients with successful drainage.",
"   </p>",
"   <p>",
"    In addition to incomplete biliary drainage, other risk factors for cholangitis have been identified in prospective studies. These include jaundice, a small endoscopy center, combined percutaneous-endoscopic procedures, and stenting of malignant strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangitis typically develops within 24 to 72 hours after ERCP in patients with failed biliary drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/4,26\">",
"     4,26",
"    </a>",
"    ]. The classic triad of Charcot (fever, right upper quadrant pain, and jaundice) occurs in only 50 to 75 percent of patients with acute cholangitis. Confusion and hypotension can occur in patients with suppurative cholangitis, producing Reynold's pentad, which is associated with significant morbidity and mortality, including multiorgan failure due to septic shock. Hypotension may be the only presenting symptom in elderly patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe cases may also be associated with the development of a hepatic abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/4,6,27,29,30\">",
"     4,6,27,29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link\">",
"     \"Pyogenic liver abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Grading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-ERCP cholangitis can be graded as mild, moderate, or severe based upon a consensus definition [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild - Temperature &gt;38&ordm;C for 24 to 48 hours",
"     </li>",
"     <li>",
"      Moderate - Febrile or septic illness requiring more than three days of hospital treatment or endoscopic or percutaneous intervention",
"     </li>",
"     <li>",
"      Severe - Septic shock or surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment of post-ERCP cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment is decompression of the obstructed duct while providing supportive care including antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute cholangitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ACUTE CHOLECYSTITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholecystitis following ERCP or percutaneous transhepatic biliary drainage may be more common than once appreciated, and must be distinguished from cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/26-28,32-38\">",
"     26-28,32-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Incidence and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of acute cholecystitis ranged from 0.1 to 8.6 percent in various reports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/32\">",
"     32",
"    </a>",
"    ], with most large series having an incidence &le;0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/27,28,39,40\">",
"     27,28,39,40",
"    </a>",
"    ]. The pathogenesis may be related to the introduction of nonsterile contrast media into a poorly emptying gallbladder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mechanical or inflammatory obstruction of the cystic duct by an endoprosthesis, malignancy, or gallstone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/33-37,40\">",
"     33-37,40",
"    </a>",
"    ]. Some reports have found an increased risk of cholecystitis following the placement of covered metal biliary stents, especially when the cystic duct is partially compromised by the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholecystitis following ERCP should be suspected in patients who develop tenderness localized in the right upper quadrant and have thickening of the gallbladder wall and pericholecystic fluid on ultrasonography or computed tomography. The risk may be increased in patients with diabetes mellitus and in those with obstruction in whom stenting was unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most centers perform early cholecystectomy after ERCP and biliary sphincterotomy for common bile duct stones, a practice that would eliminate the most likely cause of cholecystitis in patients with gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute cholecystitis following ERCP is the same as the treatment for acute cholecystitis from other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PANCREATIC INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the pancreas following ERCP is uncommon and can have a variety of manifestations. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An infected pseudocyst due to contamination following pancreatic duct injection or stone removal [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/10,39,43\">",
"       10,39,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Post-ERCP pancreatitis may be due to iatrogenic bacterial seeding of the pancreas from contaminated equipment. However, microorganisms do not appear to have a significant role in the majority of such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"       \"Post-ERCP pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREVENTION OF POST-ERCP SEPTIC COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Endoscopic technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper ERCP technique and skill in drainage procedures are of paramount importance for minimizing the risk of infection. Guidelines to avoid septic complications following ERCP can be suggested based upon the available data and consensus opinion. The following recommendations are consistent with basic principles of endoscopy and with a statement from the American Society for Gastrointestinal Endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopes must be properly cleaned and disinfected before each procedure.",
"     </li>",
"     <li>",
"      Radiographic contrast solutions must be sterile. The addition of antibiotics to contrast solutions appears to be unnecessary, but remains controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The volume of contrast injected should be the minimum necessary to obtain adequate radiographs in patients with known obstruction or cholangitis. Bile should be aspirated before injection to avoid injecting with excessive hydrostatic pressure.",
"     </li>",
"     <li>",
"      Every effort should be made to achieve prompt endoscopic decompression when biliary",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pancreatic duct obstruction has been demonstrated. Thus, diagnostic ERCP should NEVER be attempted in obstructed patients if drainage cannot be provided during the same procedure.",
"     </li>",
"     <li>",
"      When definitive endoscopic drainage cannot be achieved, temporary drainage with a nasobiliary tube or a stent is mandatory until a definitive procedure can be performed.",
"     </li>",
"     <li>",
"      If bile flow cannot be restored endoscopically, a percutaneous or surgical procedure should be undertaken without excessive delay.",
"     </li>",
"     <li>",
"      In patients with malignant hilar strictures, drainage should be selective, preferably based upon the results of magnetic resonance cholangiopancreatography (MRCP) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/48-51\">",
"       48-51",
"      </a>",
"      ], thereby avoiding unnecessary invasive imaging. Air cholangiography instead of iodine contrast might reduce the rate of cholangitis in patients with Klatskin tumors, but the safety and efficacy of this technique deserve confirmation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with biliary stents need surveillance for early detection of stent occlusion and prevention of related infectious complications; however, a consensus has not been reached on optimal surveillance strategies. In a prospective controlled trial, elective replacement of plastic stents in patients with malignant biliary strictures did not significantly improve survival compared with stent exchange only when symptoms developed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/53\">",
"       53",
"      </a>",
"      ]. It is reasonable to monitor liver biochemical tests on a monthly basis following drainage, since plastic and metal stents generally remain patent for no more than three and six months, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis is recommended in selected patients undergoing ERCP (",
"    <a class=\"graphic graphic_table graphicRef54121 \" href=\"UTD.htm?13/60/14285\">",
"     table 1",
"    </a>",
"    ). Prophylactic antibiotics were once widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/7,18\">",
"     7,18",
"    </a>",
"    ], but the benefit of using them has been difficult to establish in controlled clinical trials. Two meta-analyses published in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/54\">",
"     54",
"    </a>",
"    ] and in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/55\">",
"     55",
"    </a>",
"    ] failed to show the effectiveness of antibiotics routinely administered before ERCP. In a retrospective analysis of 11,484 ERCPs over 11 years from 1994 through 2006, the infection rate after ERCP decreased with time from 0.48 to 0.25 percent, despite a marked reduction in the proportion of patients given antibiotics, from 95 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not suggest antibiotic prophylaxis for ERCPs in the absence of cholangitis in the case of biliary obstruction. This recommendation is consistent with guidelines from the American Society for Gastrointestinal Endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23959/abstract/45,57\">",
"     45,57",
"    </a>",
"    ]. However, we do suggest antibiotic prophylaxis for ERCP in some high-risk settings, including hilar obstruction, sclerosing cholangitis, pancreatic pseudocysts, and for procedures in immunocompromised patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link&amp;anchor=H8#H8\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\", section on 'When to use antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=see_link\">",
"       \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Septic complications of endoscopic retrograde cholangiopancreatography (ERCP) include cholangitis, cholecystitis, and pancreatic sepsis.",
"     </li>",
"     <li>",
"      Signs and symptoms of cholangitis include fever, right upper quadrant pain, and jaundice. Some patients will also develop confusion, which is associated with significant morbidity and mortality.",
"     </li>",
"     <li>",
"      The diagnosis of acute cholecystitis following ERCP should be suspected in patients who develop tenderness localized in the right upper quadrant and have thickening of the gallbladder wall and pericholecystic fluid seen on ultrasound or CT.",
"     </li>",
"     <li>",
"      Infection of the pancreas following ERCP is uncommon, but can occur in patients who have a pseudocyst that becomes contaminated following pancreatic duct injection.",
"     </li>",
"     <li>",
"      The risk of infectious complications following ERCP can be minimized by adhering to proper endoscopic technique. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Endoscopic technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic prophylaxis is not generally recommended for ERCPs in the absence of cholangitis in patients with biliary obstruction (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). However, we suggest antibiotic prophylaxis in some high-risk settings, including hilar obstruction, sclerosing cholangitis, pancreatic pseudocysts, and for procedures in immunocompromised patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"       \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Failed endoscopic drainage is the most important risk factor for post-ERCP cholangitis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for cholangitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that postprocedure antibiotics be given to patients with incomplete biliary drainage following ERCP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for cholangitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous or surgical decompressive procedures should be promptly performed when adequate drainage cannot be achieved endoscopically (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for cholangitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with biliary or pancreatic stents, surveillance for early detection of stent occlusion is suggested (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Endoscopic technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/1\">",
"      Subhani JM, Kibbler C, Dooley JS. Review article: antibiotic prophylaxis for endoscopic retrograde cholangiopancreatography (ERCP). Aliment Pharmacol Ther 1999; 13:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/2\">",
"      Anderson DJ, Shimpi RA, McDonald JR, et al. Infectious complications following endoscopic retrograde cholangiopancreatography: an automated surveillance system for detecting postprocedure bacteremia. Am J Infect Control 2008; 36:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/3\">",
"      Llach J, Bordas JM, Almela M, et al. Prospective assessment of the role of antibiotic prophylaxis in ERCP. Hepatogastroenterology 2006; 53:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/4\">",
"      Devi&egrave;re J, Motte S, Dumonceau JM, et al. Septicemia after endoscopic retrograde cholangiopancreatography. Endoscopy 1990; 22:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/5\">",
"      Motte S, Deviere J, Dumonceau JM, et al. Risk factors for septicemia following endoscopic biliary stenting. Gastroenterology 1991; 101:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/6\">",
"      Davion T, Braillon A, Delamarre J, et al. Pseudomonas aeruginosa liver abscesses following endoscopic retrograde cholangiography. Report of a case without biliary tract disease. Dig Dis Sci 1987; 32:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/7\">",
"      Kullman E, Borch K, Lindstr&ouml;m E, et al. Bacteremia following diagnostic and therapeutic ERCP. Gastrointest Endosc 1992; 38:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/8\">",
"      Mollison LC, Desmond PV, Stockman KA, et al. A prospective study of septic complications of endoscopic retrograde cholangiopancreatography. J Gastroenterol Hepatol 1994; 9:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/9\">",
"      Sauter G, Grabein B, Huber G, et al. Antibiotic prophylaxis of infectious complications with endoscopic retrograde cholangiopancreatography. A randomized controlled study. Endoscopy 1990; 22:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/10\">",
"      Niederau C, Pohlmann U, L&uuml;bke H, Thomas L. Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: results of a randomized controlled clinical study. Gastrointest Endosc 1994; 40:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/11\">",
"      Byl B, Devi&egrave;re J, Struelens MJ, et al. Antibiotic prophylaxis for infectious complications after therapeutic endoscopic retrograde cholangiopancreatography: a randomized, double-blind, placebo-controlled study. Clin Infect Dis 1995; 20:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/12\">",
"      Mani V, Cartwright K, Dooley J, et al. Antibiotic prophylaxis in gastrointestinal endoscopy: a report by a Working Party for the British Society of Gastroenterology Endoscopy Committee. Endoscopy 1997; 29:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/13\">",
"      Durack DT. Prevention of infective endocarditis. N Engl J Med 1995; 332:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/14\">",
"      Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/15\">",
"      Williams EJ, Taylor S, Fairclough P, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy 2007; 39:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/16\">",
"      Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol 2009; 104:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/17\">",
"      Kager LM, Sjouke B, van den Brand M, et al. The role of antibiotic prophylaxis in endoscopic retrograde cholangiopancreatography; a retrospective single-center evaluation. Scand J Gastroenterol 2012; 47:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/18\">",
"      Deviere J, Baize M, de Toeuf J, Cremer M. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 1988; 34:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/19\">",
"      Polydorou AA, Cairns SR, Dowsett JF, et al. Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut 1991; 32:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/20\">",
"      Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998; 47:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/21\">",
"      Rerknimitr R, Attasaranya S, Kladchareon N, et al. Feasibility and complications of endoscopic biliary drainage in patients with malignant biliary obstruction at King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2002; 85 Suppl 1:S48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/22\">",
"      Bangarulingam SY, Gossard AA, Petersen BT, et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 2009; 104:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/23\">",
"      Rerknimitr R, Kladcharoen N, Mahachai V, Kullavanijaya P. Result of endoscopic biliary drainage in hilar cholangiocarcinoma. J Clin Gastroenterol 2004; 38:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/24\">",
"      Paik WH, Park YS, Hwang JH, et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009; 69:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/25\">",
"      Rerknimitr R, Fogel EL, Kalayci C, et al. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest Endosc 2002; 56:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/26\">",
"      Boender J, Nix GA, de Ridder MA, et al. Endoscopic sphincterotomy and biliary drainage in patients with cholangitis due to common bile duct stones. Am J Gastroenterol 1995; 90:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/27\">",
"      Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/28\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/29\">",
"      Khardori N, Wong E, Carrasco CH, et al. Infections associated with biliary drainage procedures in patients with cancer. Rev Infect Dis 1991; 13:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/30\">",
"      Katsinelos P, Dimiropoulos S, Katsiba D, et al. Pseudomonas aeruginosa liver abscesses after diagnostic endoscopic retrograde cholangiography in two patients with sphincter of Oddi dysfunction type 2. Surg Endosc 2002; 16:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/31\">",
"      Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/32\">",
"      Nelson DB. Infectious disease complications of GI endoscopy: part II, exogenous infections. Gastrointest Endosc 2003; 57:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/33\">",
"      Lillemoe KD, Pitt HA, Kaufman SL, Cameron JL. Acute cholecystitis occurring as a complication of percutaneous transhepatic drainage. Surg Gynecol Obstet 1989; 168:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/34\">",
"      Leung JW, Chung SC, Sung JY, Li MK. Acute cholecystitis after stenting of the common bile duct for obstruction secondary to pancreatic cancer. Gastrointest Endosc 1989; 35:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/35\">",
"      Ainley CC, Williams SJ, Smith AC, et al. Gallbladder sepsis after stent insertion for bile duct obstruction: management by percutaneous cholecystostomy. Br J Surg 1991; 78:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/36\">",
"      Dolan R, Pinkas H, Brady PG. Acute cholecystitis after palliative stenting for malignant obstruction of the biliary tree. Gastrointest Endosc 1993; 39:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/37\">",
"      Alvarez C, Hunt K, Ashley SW, Reber HA. Emphysematous cholecystitis after ERCP. Dig Dis Sci 1994; 39:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/38\">",
"      Takano H, Yoshikawa T, Nishida K, et al. Candida cholecystitis as an unusual complication of endoscopic retrograde cholangiography. Endoscopy 1996; 28:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/39\">",
"      Benchimol D, Bernard JL, Mouroux J, et al. Infectious complications of endoscopic retrograde cholangio-pancreatography managed in a surgical unit. Int Surg 1992; 77:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/40\">",
"      Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/41\">",
"      Ho H, Mahajan A, Gosain S, et al. Management of complications associated with partially covered biliary metal stents. Dig Dis Sci 2010; 55:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/42\">",
"      Cass O. Long-term complications of endoscopic biliary sphincterotomy for choledocholithiasis. Gastrointest Endosc 1998; 48:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/43\">",
"      Hawes RH. Endoscopic management of pseudocysts. Rev Gastroenterol Disord 2003; 3:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/44\">",
"      Sherman S. ERCP and endoscopic sphincterotomy-induced pancreatitis. Am J Gastroenterol 1994; 89:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/45\">",
"      ASGE STANDARDS OF PRACTICE COMMITTEE, Banerjee S, Shen B, et al. Infection control during GI endoscopy. Gastrointest Endosc 2008; 67:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/46\">",
"      Collen MJ, Hanan MR, Maher JA, Stubrin SE. Modification of endoscopic retrograde cholangiopancreatography (ERCP) septic complications by the addition of an antibiotic to the contrast media. Randomized controlled investigation. Am J Gastroenterol 1980; 74:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/47\">",
"      Bernadino KP, Howell DA, Lawrence C, et al. Near absence of septic complications following successful therapeutic ERCP justifies selective intravenous and intracontrast use of antibiotics. Gastrointest Endosc 2005; 61:AB187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/48\">",
"      Zidi SH, Prat F, Le Guen O, et al. Performance characteristics of magnetic resonance cholangiography in the staging of malignant hilar strictures. Gut 2000; 46:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/49\">",
"      Lopera JE, Soto JA, M&uacute;nera F. Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 2001; 220:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/50\">",
"      Freeman ML, Overby C. Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. Gastrointest Endosc 2003; 58:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/51\">",
"      De Palma GD, Pezzullo A, Rega M, et al. Unilateral placement of metallic stents for malignant hilar obstruction: a prospective study. Gastrointest Endosc 2003; 58:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/52\">",
"      Pisello F, Geraci G, Modica G, Scium&egrave; C. Cholangitis prevention in endoscopic Klatskin tumor palliation: air cholangiography technique. Langenbecks Arch Surg 2009; 394:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/53\">",
"      McDougall NI, Edmunds SE. An audit of metal stent palliation for malignant biliary obstruction. J Gastroenterol Hepatol 2001; 16:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/54\">",
"      Harris A, Chan AC, Torres-Viera C, et al. Meta-analysis of antibiotic prophylaxis in endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 1999; 31:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/55\">",
"      Bai Y, Gao F, Gao J, et al. Prophylactic antibiotics cannot prevent endoscopic retrograde cholangiopancreatography-induced cholangitis: a meta-analysis. Pancreas 2009; 38:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/56\">",
"      Cotton PB, Connor P, Rawls E, Romagnuolo J. Infection after ERCP, and antibiotic prophylaxis: a sequential quality-improvement approach over 11 years. Gastrointest Endosc 2008; 67:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23959/abstract/57\">",
"      ASGE Standards of Practice Committee, Anderson MA, Fisher L, et al. Complications of ERCP. Gastrointest Endosc 2012; 75:467.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 641 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23959=[""].join("\n");
var outline_f23_25_23959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PERIPROCEDURAL BACTEREMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASCENDING CHOLANGITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors for cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Grading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment of post-ERCP cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ACUTE CHOLECYSTITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Incidence and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PANCREATIC INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREVENTION OF POST-ERCP SEPTIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Endoscopic technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/641\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/641|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/60/14285\" title=\"table 1\">",
"      Abx prophylaxis regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=related_link\">",
"      Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20072?source=related_link\">",
"      Post-ERCP perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=related_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_25_23960="Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection";
var content_f23_25_23960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23960/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23960/contributors\">",
"     Thomas J Borody, MD, PhD, FRACP, FACG, FACP, AGAF",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23960/contributors\">",
"     Sharyn Leis, RN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23960/contributors\">",
"     Gerald Pang, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23960/contributors\">",
"     Antony R Wettstein, MBBS (Hons), FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23960/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23960/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23960/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/25/23960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse of",
"    <em>",
"     Clostridium",
"    </em>",
"    <em>",
"     difficile (C. difficile)",
"    </em>",
"    occurs in 10 to 25 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . Furthermore, multiple relapses in the same patient are common, and up to 10 or more bouts of relapsing colitis have occurred in some patients. Cumulative experience from case series and reports shows that fecal bacteriotherapy has been used successfully to treat relapsing",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/1\">",
"     1",
"    </a>",
"    ] and, more recently, for inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The term fecal microbiota transplantation (FMT) is preferable to fecal bacteriotherapy as it is unknown whether its efficacy is due to one or more bacteria or other gut microorganisms or agents acting alone or in combination.",
"   </p>",
"   <p>",
"    This topic will review the use of FMT for the treatment of patients with recurrent",
"    <em>",
"     C. difficile",
"    </em>",
"    infection. Other issues related to",
"    <em>",
"     C. difficile",
"    </em>",
"    infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11299153\">",
"    <span class=\"h1\">",
"     RATIONALE FOR FECAL MICROBIOTA TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal tract harbors a stable, highly complex community of microorganisms which exists in symbiosis with the host. The human gut microbiota is estimated to consist of as many as 1000 to 1200 bacterial species and at least 10",
"    <sup>",
"     14",
"    </sup>",
"    bacteria, most of which are in the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/4\">",
"     4",
"    </a>",
"    ]. The beneficial roles mediated by the microbiota for the host include the synthesis of vitamins, the fermentation of dietary carbohydrates, the metabolism of bile and host hormones and competitive exclusion (\"colonization resistance\") of pathogens taking residence in the gut community [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/5\">",
"     5",
"    </a>",
"    ]. The microbiota also influences the development and maturation of the immune system through interactions with the gut epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The composition of the microbiota is significantly affected by the extensive use of antibiotics which could lead to a selective removal of a group of bacteria species that serve as a barrier to colonization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistence of pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Antibiotic-mediated changes in the composition of the gut microbiota may also lead to homeostatic imbalance through alterations in the gut barrier functions and result in mucosal immune defects, which would predispose the host to enteric infections such as",
"    <em>",
"     C. difficile",
"    </em>",
"    by allowing environmentally acquired spores to germinate and successfully colonize the gut [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although specific antimicrobial therapy is effective against",
"    <em>",
"     C. difficile",
"    </em>",
"    infection, recurrence of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection is an increasing problem following therapy. Recurrent",
"    <em>",
"     C. difficile",
"    </em>",
"    is associated with a decrease in fecal microbial diversity deficient in",
"    <em>",
"     Bacteroides",
"    </em>",
"    and",
"    <em>",
"     Firmicutes",
"    </em>",
"    ,",
"    <em>",
"    </em>",
"    both of which generally dominate within the gut microbiota [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"    Transplantation of stool from healthy individuals to patients with recurrent",
"    <em>",
"     C. difficile",
"    </em>",
"    restores these",
"    <em>",
"    </em>",
"    strains and breaks the cycle of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H123934\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal microbiota transplantation (FMT) is employed in patients with severe and recurrent",
"    <em>",
"     C. difficile",
"    </em>",
"    infection who have failed multiple attempts at conventional antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link&amp;anchor=H7#H7\">",
"     \"Clostridium difficile in adults: Treatment\", section on 'Recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both observational studies and a randomized trial have demonstrated efficacy of fecal microbiota transplantation (FMT) in the treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    -associated diarrhea in patients with recurrent disease after initial antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/11,17-31\">",
"     11,17-31",
"    </a>",
"    ]. Limited observational data also suggests that treatment with FMT is associated with resolution of",
"    <em>",
"     C. difficile",
"    </em>",
"    -associated diarrhea in patients with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/19,31-33\">",
"     19,31-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H10#H10\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Fulminant colitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several routes have been used to administer fecal microbiota with cure rates ranging from 81 to 94 percent in patients with recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/29,30,34\">",
"     29,30,34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H86428661\">",
"     'Efficacy based on route of administration'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5\">",
"     'Suggested protocol'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In studies where the time to response has been specified, it has been observed within 24 hours to 12 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/2,24,35-37\">",
"     2,24,35-37",
"    </a>",
"    ]. In one study with variable follow-up ranging from three weeks to eight years, the response appeared to be durable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/20\">",
"     20",
"    </a>",
"    ]. In our experience, patients also showed an immediate and complete resolution of diarrhea and associated symptoms and disappearance of pseudomembranes if initially present. Following treatment, repeated stool tests for",
"    <em>",
"     C. difficile",
"    </em>",
"    and toxins were negative.",
"   </p>",
"   <p>",
"    FMT remains the only method capable of providing durable implantation of probiotics, with results demonstrating that infused donor fecal microbiota remains largely stable in composition over a 24-week period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/14\">",
"     14",
"    </a>",
"    ]. Attempts to reconstitute the bacterial microbiota using cultured bacteria have not been successful, with the exception of a single report of freshly cultured bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/11,38-40\">",
"     11,38-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86428661\">",
"    <span class=\"h2\">",
"     Efficacy based on route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several routes of administration of fecal intestinal microbiota have been reported but the optimal protocol for fecal microbiota (FMT) transplant is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/17,18,20,22,24-26,30,41,42\">",
"     17,18,20,22,24-26,30,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11299920\">",
"    <span class=\"h3\">",
"     Administration via enema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have shown success with FMT administered via enema [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/11,19,26,35,36,41\">",
"     11,19,26,35,36,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 16 patients with severe, refractory disease treated during an 18-year period, 13 patients responded dramatically with decreases in diarrhea, temperature, and leukocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/35\">",
"       35",
"      </a>",
"      ]. Three of the patients died, but two did not have pseudomembranes at autopsy, while the third patient failed treatment and had small bowel involvement with pseudomembranes detected at autopsy. No adverse effects from the fecal enemas were noted.",
"     </li>",
"     <li>",
"      In another report of nine patients, a single administration of a fecal enema (5 to 10 g homogenized stool in pasteurized cow's milk) was effective in seven of nine patients, but the response (relief of diarrhea) was delayed for up to five days [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/36\">",
"       36",
"      </a>",
"      ]. No relapses occurred during 18 months of follow-up.",
"     </li>",
"     <li>",
"      A case series of 27 patients with refractory or recurrent",
"      <em>",
"       C. difficile",
"      </em>",
"      underwent FMT via retention enema using stool from two healthy donors [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/28\">",
"       28",
"      </a>",
"      ]. After FMT, 25 of 27 (93 percent) patients experienced clinical resolution. Of these, 22 resolved within 24 hours of FMT. Of the five patients who underwent a repeat FMT for recurrence of diarrhea, three had symptom resolution and two continued to experience diarrhea despite two repeat FMTs. No relapse or adverse events occurred in patients who were successfully treated with FMT, with a mean follow-up time of 427 days after FMT.",
"     </li>",
"     <li>",
"      Self-administered home fecal transplantation for recurrent",
"      <em>",
"       C. difficile",
"      </em>",
"      infection has also been successfully performed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/21\">",
"       21",
"      </a>",
"      ]. Recipients and donors were given instructions that included equipment needs, medication use, stool preparation, and administration. Stool infusate (~250 mL) was self-administered or administered by a family member using an enema and retained as long as possible. The seven patients who underwent the procedure were cured of",
"      <em>",
"       C. difficile",
"      </em>",
"      infection with up to 14 months of follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of FMT may depend upon the technique used to cleanse the colon before administration of the fecal enema [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/18\">",
"     18",
"    </a>",
"    ]. Cleansing (eg, with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    lavage) may reduce the density of",
"    <em>",
"     C. difficile",
"    </em>",
"    organisms including the metabolically inactive spores that could otherwise convert to vegetative forms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link&amp;anchor=H148494535#H148494535\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\", section on 'Polyethylene glycol solutions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Administration via colonoscope",
"    </strong>",
"    &mdash; In contrast to enemas which can generally only reach the splenic flexure, colonoscopy allows for the administration of the bacteria throughout the colon and possibly the distal small bowel where",
"    <em>",
"     C. difficile",
"    </em>",
"    can reside. A number of studies have demonstrated that a single administration has been extremely efficacious in eradicating",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/13,16,18,20\">",
"     13,16,18,20",
"    </a>",
"    ]. Given the ease of administration in both inpatient and outpatient settings, and the delivery of the introduced flora to the site where most",
"    <em>",
"     C. difficile",
"    </em>",
"    is located, administration via a colonoscope has been proposed as the preferential route of delivery of fecal microbiota [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/32\">",
"     32",
"    </a>",
"    ]. However, colonoscopy must be performed extremely cautiously in this setting because of the risk of perforation.",
"   </p>",
"   <p>",
"    Studies using colonoscopic delivery have also shown promising results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nineteen patients with recurrent",
"      <em>",
"       C. difficile",
"      </em>",
"      infections who failed standard therapy achieved a cure by infusion of donor stool suspension through a colonoscope [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/16\">",
"       16",
"      </a>",
"      ]. One patient required a second infusion. Patients remained symptom free at follow-up ranging from six months to five years, but three patients developed recurrent",
"      <em>",
"       C. difficile",
"      </em>",
"      infection after taking prescribed antibiotics for unrelated infections. The study suggests that the structure and function of the gut microbial community once restored is not permanent and is vulnerable to disruption by antibiotic use for unrelated infections.",
"     </li>",
"     <li>",
"      In a study of 12 patients with",
"      <span class=\"nowrap\">",
"       recurrent/refractory",
"      </span>",
"      <em>",
"       C. difficile",
"      </em>",
"      infection, including nine patients with diverticulosis, direct instillation of stool throughout the entire colon resulted in a 100 percent cure rate [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       Spouses/partners",
"      </span>",
"      accounted for 8 of 12 donors. Clinical response to fecal transplantation was durable with a follow-up range of three weeks to eight years.",
"     </li>",
"     <li>",
"      Twenty-six patients with relapsing",
"      <em>",
"       C. difficile",
"      </em>",
"      underwent FMT over a 28-month period [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/43\">",
"       43",
"      </a>",
"      ]. After receiving a stool suspension (typically a partner or a family member as donor), the patients were followed for an average 10.7 months. Twenty-four patients (92 percent) remained completely symptom-free, with most patients reporting immediate improvement within hours or a few days following FMT.",
"     </li>",
"     <li>",
"      Seventy patients with recurrent",
"      <em>",
"       C. difficile",
"      </em>",
"      who had undergone FMT were reviewed from medical records [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/44\">",
"       44",
"      </a>",
"      ]. During the first 12 weeks, patients not infected with the 027",
"      <em>",
"       C. difficile",
"      </em>",
"      strain had their symptoms resolved. Of the 36 patients infected with the 027 strain, 32 patients (89 percent) responded to FMT. Four nonresponder patients had a serious long-lasting diarrheal disease or comorbidity and subsequently died of colitis. During the first year, four responder patients had a relapse after taking antibiotics for unrelated causes. Of these, two were successfully treated with another FMT and two with antibiotics for",
"      <em>",
"       C. difficile",
"      </em>",
"      infections. Ten patients who had FMT died of unrelated illness within one year. No adverse effects of FMT were observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11299943\">",
"    <span class=\"h3\">",
"     Administration via nasogastric tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration via a nasogastric tube also permits delivery of the bacteria to the distal small bowel and throughout the colon. FMT administered via nasogastric tube has been demonstrated to be successful in several observational studies and a randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/22-25,30\">",
"     22-25,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open label randomized controlled trial, 43 patients with recurrent",
"      <em>",
"       C. difficile",
"      </em>",
"      infection after at least one course of antibiotic therapy, were randomized to duodenal infusion of donor feces preceded by an abbreviated regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (vancomycin 500 mg four times daily for four days) and bowel lavage (4 L of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"       polyethylene glycol",
"      </a>",
"      ), a standard vancomycin regimen (vancomycin 500 mg four times daily for 14 days), or standard vancomycin regimen with bowel lavage [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/30\">",
"       30",
"      </a>",
"      ]. Single infusion of donor feces was associated with significantly higher rates of resolution of",
"      <em>",
"       C. difficile-",
"      </em>",
"      associated diarrhea without relapse at 10 weeks as compared with a standard vancomycin regimen with or without bowel lavage (81, 23, and 31 percent, respectively). Mild diarrhea, cramping, and belching that resolved within three hours of the infusion of feces were the most common side effects (94, 31, and 19 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11300118\">",
"    <span class=\"h2\">",
"     Patients who have undergone subtotal colectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal evidence suggests that FMT may be less effective in patients who have previously undergone subtotal colectomy. However, a randomized trial is needed to confirm these observations and to determine the optimal route of administration in such patients (eg, nasogastric tube or enema).",
"   </p>",
"   <p>",
"    In the authors' experience with three patients who had subtotal colectomies for indications other than",
"    <em>",
"     C. difficile",
"    </em>",
"    who subsequently developed",
"    <em>",
"     C. difficile",
"    </em>",
"    , up to six FMT treatments (given by both nasogastric tube and enema) failed to cure the",
"    <em>",
"     C. difficile",
"    </em>",
"    infection.&nbsp;",
"   </p>",
"   <p>",
"    This suggests that fecal bacteriotherapy may lose its efficacy when patients have had a subtotal colectomy. These observations also suggest that it may be important to treat a patient with severe",
"    <em>",
"     C. difficile",
"    </em>",
"    colitis with FMT before a colectomy is necessary, because once a colectomy is performed, FMT may no longer be an effective treatment option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patients with underlying inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     C. difficile",
"    </em>",
"    infection can exacerbate underlying inflammatory bowel disease (IBD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FMT has been successful in treating patients with IBD and refractory",
"    <em>",
"     C. difficile",
"    </em>",
"    in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of six patients (four with ulcerative colitis and two with Crohn's disease) who were positive for",
"      <em>",
"       C. difficile",
"      </em>",
"      and failed to respond to antibiotic therapies, FMT led to eradication of",
"      <em>",
"       C. difficile",
"      </em>",
"      (determined by stool test and toxin",
"      <span class=\"nowrap\">",
"       A/B",
"      </span>",
"      assays) with marked symptom resolution in all six patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/45\">",
"       45",
"      </a>",
"      ]. Despite a reduction in diarrhea, abdominal pain, mucus, and flatulence, one patient required surgical intervention three months after",
"      <em>",
"       C. difficile",
"      </em>",
"      eradication due to noncompliance with IBD medications.",
"     </li>",
"     <li>",
"      In a study of 14 IBD patients (six with Crohn's disease, four with ulcerative colitis, and four with lymphocytic colitis) with recurrent",
"      <em>",
"       C. difficile",
"      </em>",
"      , although two Crohn's disease patients required a second infusion to clear the infection, FMT was effective in clearing the infection using either standard frozen stool or patient selected fresh stool. No adverse effects of FMT were observed. [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal microbiota transplantation (FMT) appears to be safe. Major complications have not been reported in published series [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/1,48\">",
"     1,48",
"    </a>",
"    ], although some risks may be associated with use of a nasogastric tube and colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/25\">",
"     25",
"    </a>",
"    ]. Adverse effects have been transient and mild and consist mainly of abdominal gurgling, gas, and noise, which are expected symptoms following administration via an enema [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lingering concern is the potential of transmission of infectious agents contained in the stool. The risk may be reduced by obtaining stool from healthy donors with normal bowel function and by testing both stool and blood for common viral and bacterial pathogens and parasites [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/21,23\">",
"     21,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUGGESTED PROTOCOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with fecal microbiota transplantation (FMT) has been hampered by a lack of standardization in the preparation and administration of the fecal suspension. Efficacy appears to depend upon a number of factors including the freshness of donated stool, the frequency of enema administration, the use of colonic lavage, and repopulation of the entire colon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following protocol for administration via the lower gastrointestinal (GI) tract (based upon our clinical experience) has been effective in achieving prolonged cure in approximately 90 percent of our patients, with long-term resolution of symptoms (no diarrhea, abdominal pain or cramping, and negative stool toxin tests and",
"    <em>",
"     C. difficile",
"    </em>",
"    culture). In addition, several of our patients have subsequently received antibiotics and have not relapsed.",
"   </p>",
"   <p>",
"    An alternate approach is to administer the suspension via the upper GI tract (see",
"    <a class=\"local\" href=\"#H123835\">",
"     'Administration via the upper GI tract'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H123827\">",
"    <span class=\"h2\">",
"     Administration via the lower GI tract",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donor stool and blood are screened for pathogens and viruses before infusion. We perform a complete blood count and serological testing for hepatitis A, B, and C; HIV-1 and HIV-2; and syphilis. Stool cultures are obtained to look for enteric bacterial pathogens and light microscopy examination of stool samples is carried out for ova and parasites. Donor stool should also be screened for",
"      <em>",
"       C. difficile",
"      </em>",
"      to rule out asymptomatic carriage. Clinically, the donor needs to have normal, daily stools, no recent antibiotics (ie, not in the last six months), no history of inflammatory bowel disease, and be clinically well. A relative or friend may be a donor. However, we do not believe donors should share living quarters with the patient, as there is likelihood that they will share the same defective microbiota.",
"     </li>",
"     <li>",
"      The recipient's HIV and hepatitis A and B status is also checked prior to receipt of FMT.",
"     </li>",
"     <li>",
"      We administer oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (500 mg twice daily for seven days) followed by a single oral lavage with 3 to 4 liters of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"       polyethylene glycol",
"      </a>",
"      with electrolytes purgative (such as GoLYTELY&reg;). We forego the lavage in patients too ill to tolerate it, but use the vancomycin pretreatment whenever possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link&amp;anchor=H148494535#H148494535\">",
"       \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\", section on 'Polyethylene glycol solutions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We use 200 to 300 g of donor stool suspended in 200 to 300 mL of sterile normal saline (homogenized briefly in kitchen blender to a liquid consistency) administered via enema within 10 minutes of preparation, repeated daily for five days.",
"     </li>",
"     <li>",
"      We encourage patients to retain the enema for at least six hours. Some patients are unable to retain the enema initially for prolonged periods. Nevertheless, coating of the mucosa by the infusate appears to be adequate. Pretreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      (2 mg, followed by an additional 2 mg every two hours, up to a total of 8 mg), may help with retention of the enema. During the treatment period, patients are advised to adhere to a high fiber diet to assist in the support of infused bacteria (",
"      <a class=\"graphic graphic_table graphicRef82094 \" href=\"UTD.htm?17/1/17438\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The initial infusion may be filtered and infused via colonoscopy, preferably into the terminal ileum, to address known ileal presence of",
"      <em>",
"       C. difficile",
"      </em>",
"      . One study demonstrated that in the less severely affected patients, a single colonoscopic infusion of 200 to 300 g of stool suspension throughout the colon will suffice to cure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/20\">",
"       20",
"      </a>",
"      ]. However, in patients with colonic inflammation, the risk of colon perforation is increased, so if this method is used, it should be done with extreme care. Following endoscopic infusion, we suggest that at least five days of rectal enemas be administered daily using donor stool.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H123835\">",
"    <span class=\"h2\">",
"     Administration via the upper GI tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternate route of administration is via a nasogastric (NG) or nasojejunal tube (NJ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23960/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient and stool preparation is similar to the procedure used for patients receiving their suspension via the lower GI tract. However, in addition to antibiotics and preparation with a purgative, patients should receive a dose of a proton pump inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      20 mg) the evening before and the morning of the instillation to decrease gastric acid.",
"     </li>",
"     <li>",
"      An NG or NJ tube is placed into the upper GI tract. While the patient is under sedation, an NG or NJ tube is inserted through the nostril and advanced into the small bowel. The positioning is confirmed by x-ray and Gastrografin follow-through before proceeding with the infusion. It is recommended that the tube remain in situ for a period of five days to administer the infusion.",
"     </li>",
"     <li>",
"      A single instillation of 25 to 30 g of stool diluted in 50 mL of saline is typically sufficient in patients receiving the therapy via the upper GI tract.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=see_link\">",
"       \"Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=see_link\">",
"       \"Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent and severe",
"      <em>",
"       Clostridium difficile (C. difficile)",
"      </em>",
"      infection despite antibiotic therapy is increasingly common. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Restoration of the normal fecal microbiota may be important for resolving infection refractory to oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      . However, the exact complement of fecal bacteria that are required to restore a normal fecal microbiota is unclear. Fecal microbiota transplantation (FMT) offers a means to durably restore the normal microbiota. (See",
"      <a class=\"local\" href=\"#H11299153\">",
"       'Rationale for fecal microbiota transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment with FMT, at a center of expertise, in patients with recurrent",
"      <em>",
"       C. difficile",
"      </em>",
"      infection who have failed multiple courses of antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"       \"Clostridium difficile in adults: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal means to prepare and instill the microbiota are being defined. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Suggested protocol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FMT appears to be safe. Risks include those associated with the use of nasogastric tubes and with colonoscopy. Another concern is the potential of transmission of infectious agents contained in the stool. The risk may be reduced by obtaining stool from healthy donors with normal bowel function and by testing both stool and blood for common viral and bacterial pathogens and parasites. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Safety'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Suggested protocol'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31178?source=see_link&amp;anchor=H133249458#H133249458\">",
"       \"Overview of colonoscopy in adults\", section on 'Complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=see_link&amp;anchor=H522922014#H522922014\">",
"       \"Nasogastric and nasoenteric tubes\", section on 'Complications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/1\">",
"      Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009; 15:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/2\">",
"      Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/3\">",
"      Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/4\">",
"      Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/5\">",
"      Robinson CJ, Bohannan BJ, Young VB. From structure to function: the ecology of host-associated microbial communities. Microbiol Mol Biol Rev 2010; 74:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/6\">",
"      Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 2010; 330:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/7\">",
"      Sharma R, Young C, Neu J. Molecular modulation of intestinal epithelial barrier: contribution of microbiota. J Biomed Biotechnol 2010; 2010:305879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/8\">",
"      Jernberg C, L&ouml;fmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/9\">",
"      Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011; 108 Suppl 1:4554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/10\">",
"      Reid G, Younes JA, Van der Mei HC, et al. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 2011; 9:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/11\">",
"      Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/12\">",
"      Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/13\">",
"      Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/14\">",
"      Grehan MJ, Borody TJ, Leis SM, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010; 44:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/15\">",
"      Floch MH. Fecal bacteriotherapy, fecal transplant, and the microbiome. J Clin Gastroenterol 2010; 44:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/16\">",
"      Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010; 44:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/17\">",
"      Schwan A, Sj&ouml;lin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984; 16:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/18\">",
"      Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000; 95:3283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/19\">",
"      You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med 2008; 148:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/20\">",
"      Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 2010; 44:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/21\">",
"      Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010; 8:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/22\">",
"      MacConnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 2009; 102:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/23\">",
"      Nieuwdorp M, van Nood E, Speelman P, et al. [Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces]. Ned Tijdschr Geneeskd 2008; 152:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/24\">",
"      Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics 2010; 126:e239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/25\">",
"      Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/26\">",
"      Faust G, Langelier D, Haddad H, et al. Treatment of recurrent pseudomembranous colitis with stool transplantation: Report of six cases. Can J Gasteroenterol 2002; 16:A43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/27\">",
"      Landy J, Al-Hassi HO, McLaughlin SD, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011; 34:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/28\">",
"      Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 2012; 172:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/29\">",
"      Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/30\">",
"      van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/31\">",
"      Trubiano JA, Gardiner B, Kwong JC, et al. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol 2013; 25:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/32\">",
"      Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: \"first-line\" treatment for severe clostridium difficile infection? J Clin Gastroenterol 2011; 45:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/33\">",
"      Gallegos-Orozco JF, Paskvan-Gawryletz CD, Gurudu SR, Orenstein R. Successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis. Rev Gastroenterol Mex 2012; 77:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/34\">",
"      Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/35\">",
"      Bowden TA Jr, Mansberger AR Jr, Lykins LE. Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg 1981; 47:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/36\">",
"      Gustafsson A, Lund-T&oslash;nnesen S, Berstad A, et al. Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol 1998; 33:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/37\">",
"      Garborg K, Waagsb&oslash; B, Stallemo A, et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2010; 42:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/38\">",
"      Bouhnik Y, Pochart P, Marteau P, et al. Fecal recovery in humans of viable Bifidobacterium sp ingested in fermented milk. Gastroenterology 1992; 102:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/39\">",
"      Kullen MJ, Amann MM, O'Shaughnessy MJ, et al. Differentiation of ingested and endogenous bifidobacteria by DNA fingerprinting demonstrates the survival of an unmodified strain in the gastrointestinal tract of humans. J Nutr 1997; 127:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/40\">",
"      McNulty NP, Yatsunenko T, Hsiao A, et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med 2011; 3:106ra106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/41\">",
"      EISEMAN B, SILEN W, BASCOM GS, KAUVAR AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/42\">",
"      Fl&oslash;tter&oslash;d O, Hopen G. [Refractory Clostridium difficile infection. Untraditional treatment of antibiotic-induced colitis]. Tidsskr Nor Laegeforen 1991; 111:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/43\">",
"      Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012; 46:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/44\">",
"      Mattila E, Uusitalo-Sepp&auml;l&auml; R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012; 142:490.",
"     </a>",
"    </li>",
"    <li>",
"     Borody TJ, Wettstein AR, Hills L, et al. Clostrodium difficile infection complicating inflammatory bowel disease: pre-treatment and post-treatment findings. Abstract accepted for DDW, San Diego, CA, 17-22 May 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/46\">",
"      Duplessis CA, You D, Johnson M, Speziale A. Efficacious outcome employing fecal bacteriotherapy in severe Crohn's colitis complicated by refractory Clostridium difficile infection. Infection 2012; 40:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/47\">",
"      Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23960/abstract/48\">",
"      Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004; 38:475.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2604 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23960=[""].join("\n");
var outline_f23_25_23960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11299153\">",
"      RATIONALE FOR FECAL MICROBIOTA TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H123934\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86428661\">",
"      Efficacy based on route of administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11299920\">",
"      - Administration via enema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11299943\">",
"      - Administration via nasogastric tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11300118\">",
"      Patients who have undergone subtotal colectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patients with underlying inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUGGESTED PROTOCOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H123827\">",
"      Administration via the lower GI tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H123835\">",
"      Administration via the upper GI tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2604\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2604|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/1/17438\" title=\"table 1\">",
"      Dietary fiber content of frequently consumed foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=related_link\">",
"      Nasogastric and nasoenteric tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31178?source=related_link\">",
"      Overview of colonoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_25_23961="Efavirenz, tenofovir, and emtricitabine: Drug information";
var content_f23_25_23961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Efavirenz, tenofovir, and emtricitabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/23/25973?source=see_link\">",
"    see \"Efavirenz, tenofovir, and emtricitabine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/4/36937?source=see_link\">",
"    see \"Efavirenz, tenofovir, and emtricitabine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3053105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atripla&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5505100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atripla&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3053108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Non-nucleoside);",
"     </li>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside);",
"     </li>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleotide)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3053160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral: One tablet once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended as an initial regimen for antiretroviral-naive patients (DHHS, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F15044040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/4/36937?source=see_link\">",
"      see \"Efavirenz, tenofovir, and emtricitabine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Children &ge;12 years and &ge;40 kg and Adolescents: Oral: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3053161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate-to-severe renal impairment  (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute):  Use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12807218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild hepatic impairment (Child-Pugh class A): Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate or severe hepatic impairment (Child-Pugh class B, C): Not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3053167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atripla&reg;: Efavirenz 600 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9848865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3053163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken on an empty stomach, normally at bedtime to increase gastrointestinal tolerance and decrease nervous system manifestations.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3053110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3053141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The complete adverse reaction profile of combination therapy has not been established.",
"     <b>",
"      See individual agents.",
"     </b>",
"     The following adverse effects were noted in clinical trials with combination therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Endocrine &amp; metabolic: Hypercholesterolemia (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Depression (9%), fatigue (9%), dizziness (8%), headache (6%), anxiety (5%), insomnia (5%), somnolence (4%), abnormal dreams",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (4%), hyperglycemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (9%), diarrhea (9%), serum amylase increased (8%),  vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (3%), ALT increased (2%), alkaline phosphatase increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Creatine increased (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Hematuria (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Sinusitis (8%), upper respiratory infection (8%), nasopharyngitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Glycosuria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3053116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of clinically-significant  hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin reactions) to efavirenz, concurrent use of bepridil, cisapride, midazolam, triazolam, voriconazole, ergot alkaloids (includes dihydroergotamine, ergotamine, ergonovine, methylergonovine), St John's wort, pimozide",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3053117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression (eg, impaired concentration, dizziness or drowsiness); avoid potentially hazardous tasks such as driving or operating machinery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone mineral density: Use has been associated with decreases in bone mineral density (~5% to 7%) and osteomalacia which may lead to fractures. Consider monitoring of bone density in patients at risk for osteopenia or with a history of pathologic fractures; consider calcium and vitamin D supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis). Some cases of hepatotoxicity have occurred in patients with no hepatic disease prior to treatment. Persistent elevations of serum transaminases &gt;5 times the upper limit of normal should prompt evaluation - benefit of continued therapy should be weighed against possible risk of hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric effects: Serious psychiatric side effects have been associated with use, including severe depression, suicide, paranoia, and mania; use with caution in patients with a history of mental illness/drug abuse (predisposition to psychological reactions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rash: Discontinue if severe rash (involving blistering, desquamation, mucosal involvement or fever) develops. Children are more susceptible to development of rash (median time to onset: 8 days); prophylactic antihistamines may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: May cause renal toxicity (acute renal failure and/or Fanconi syndrome); avoid use with concurrent or recent nephrotoxic therapy; monitor renal function during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S. Boxed Warning]: Safety and efficacy during coinfection of HIV and HBV have not been established; acute, severe exacerbations of HBV have been reported following discontinuation of antiretroviral therapy. Not indicated for treatment of chronic hepatitis B.",
"     </b>",
"     All patients with HIV should be tested for HBV prior to initiation of treatment. Caution in patients with known or suspected hepatitis B or C infection (monitoring of liver function is recommended). In HBV coinfected patients, monitor hepatic function closely for several months following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Not recommended in patients with moderate or severe hepatic impairment (Child-Pugh class B, C). Use caution in patients with mild hepatic impairment (Child-Pugh class A), HBV or HCV coinfection, elevated transaminases or use of concomitant hepatotoxic drugs. Monitor liver function tests before and during treatment; some cases of hepatic failure have developed in patients with no hepatic disease prior to treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Product is a fixed-dose combination and is not appropriate for use in renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; seizures have been associated with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adefovir: Do not use concurrently with adefovir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duplicate therapy: Do not use concurrently with efavirenz emtricitabine, tenofovir, or any combination of these drugs; however, coadministration with efavirenz may be required for dose-adjustment with concomitant rifampin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: High potential for CYP-mediated drug interactions; consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.  See Drug Interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lamivudine: Do not use concurrently with lamivudine or lamivudine-combination products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Fixed-dose combination product; safety and efficacy have not been established in patients &lt;12 years of age and &lt;40 kg. In children &lt;40 kg, the dose of efavirenz would be excessive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Avoid pregnancy; women of childbearing potential should undergo pregnancy testing prior to initiation of therapy. Two forms of contraception should be used during and for 12 weeks after discontinuation of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3053147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3053146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May decrease the excretion of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adefovir: May diminish the therapeutic effect of Tenofovir. Specifically, adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir. Management: When combined use required, tenofovir 300 mg and atazanavir 300 mg should be used with ritonavir 100 mg (adult doses), all given in single daily dose with food.   Atazanavir without ritonavir should not be used with tenofovir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Efavirenz may decrease the serum concentration of Atazanavir.  Management: When used with efavirenz, the atazanavir regimen should be atazanavir 400 mg/ritonavir 100 mg daily for treatment-naive patients; treatment-experienced patients should not use atazanavir together with efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Efavirenz may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Efavirenz may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: Efavirenz may enhance the arrhythmogenic effect of Bepridil [Off Market].",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Efavirenz may decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Efavirenz may decrease the serum concentration of BuPROPion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Efavirenz may enhance the QTc-prolonging effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Efavirenz may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Increase monitoring of cyclosporine concentrations when starting, stopping, or adjusting doses of concurrent efavirenz, particularly within the first 2 weeks.  Cyclosporine dose adjustment may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Tenofovir may diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir and didanosine.  Consider altering even existing, stable treatment to avoid this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Efavirenz may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Efavirenz may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Efavirenz may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Efavirenz may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etonogestrel: Efavirenz may diminish the therapeutic effect of Etonogestrel.  Management: Use a reliable barrier contraceptive if efavirenz is used in combination with etonogestrel.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: Efavirenz may decrease the serum concentration of Everolimus.  Management: Closely monitor everolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of everolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Efavirenz may decrease serum concentrations of the active metabolite(s) of Fosamprenavir.  Management: For once-daily fosamprenavir/ritonavir with efavirenz, an increased ritonavir dose to 300 mg/day is recommended.  No ritonavir dose adjustment is required if using twice-daily fosamprenavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Efavirenz may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Tenofovir may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Efavirenz may decrease the serum concentration of Indinavir.  Management: The appropriate dose adjustments for indinavir when used together with efavirenz are unknown. The use of higher unboosted indinavir doses is not likely an adequate approach.  Use of a ritonavir-boosted indinavir regimen could be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Efavirenz may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: May enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Efavirenz may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with efavirenz.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for specific recommended dose increases in particular patient populations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Efavirenz may decrease the serum concentration of Lovastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Efavirenz may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Efavirenz may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Efavirenz. Management: Use efavirenz with caution, and monitor for increased adverse effects, during and 2 weeks following discontinuation of mifepristone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Efavirenz may enhance the adverse/toxic effect of Nevirapine. Nevirapine may enhance the adverse/toxic effect of Efavirenz. Nevirapine may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norgestimate: Efavirenz may decrease serum concentrations of the active metabolite(s) of Norgestimate.  Management: Use a reliable barrier contraceptive if efavirenz is used in combination with norgestimate.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Efavirenz may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Efavirenz may enhance the arrhythmogenic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Efavirenz may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Efavirenz may decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proguanil: Efavirenz may decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Tenofovir may decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Efavirenz may decrease the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Efavirenz may decrease the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Efavirenz.  Management: If efavirenz is to be used with daily rifabutin, increase the planned rifabutin adult dose by 50%.  If used with regimens where rifabutin is administered 2-3 times per week, consider doubling the rifabutin dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Efavirenz. Management: Increase efavirenz adult dose to 800 mg daily in patients weighing over 50 kg (per U.S. manufacturer; CDC sets this at 60 kg, and Canadian manufacturer recommends the dose increase regardless of weight).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Efavirenz may enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May enhance the adverse/toxic effect of Efavirenz. Efavirenz may decrease the serum concentration of Saquinavir. Management: When used together with efavirenz, saquinavir should not be used as the sole protease inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Efavirenz may decrease the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Efavirenz may decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Efavirenz may decrease the serum concentration of Sirolimus.  Management: Closely monitor sirolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of sirolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Efavirenz may decrease the serum concentration of Tacrolimus (Systemic).  Management: Closely monitor tacrolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of tacrolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Efavirenz may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Efavirenz may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Efavirenz may increase the serum concentration of Vitamin K Antagonists. Efavirenz may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole. Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3053150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase hepatotoxic potential of efavirenz. Ethanol may also increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Avoid high-fat meals (increase the absorption of efavirenz). Food decreases peak plasma concentrations of emtricitabine, but does not alter the extent of absorption or overall systemic exposure. Fatty meals may increase the bioavailability of tenofovir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease efavirenz serum levels. Concurrent use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3053111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3053112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3053114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3053115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3053162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Should be taken on an empty stomach. In patients with history of bone fracture or osteopenia, consider calcium and vitamin D supplementation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Atripla Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600-200-300 mg (30): $2253.88",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3053165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Testing for HBV is recommended prior to the initiation of antiretroviral therapy. Monitor CBC with differential, reticulocyte count, serum creatine kinase, CD4 count, HIV RNA plasma levels, renal and hepatic function tests, cholesterol, triglycerides, bone density (long-term), serum phosphorus. Serum transaminases (discontinuation of treatment should be considered for persistent elevations &gt;5 times ULN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients with HIV and HBV coinfection should have hepatic function monitored for several months following discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5505139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Atripla (AT, AU, BE, CH, CZ, DE, DK, EE, FR, GB, GR, HK, IE, IL, IT, NL, NO, NZ, PL, PT, SE, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3053155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3053157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gallant JE, DeJesus E, Arribas JR, et al, &ldquo;Tenofovir DF, Emtricitabine, and Efavirenz vs Zidovudine, Lamivudine, and Efavirenz for HIV,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(3):251-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/25/23961/abstract-text/16421366/pubmed\" id=\"16421366\" target=\"_blank\">",
"        16421366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8858 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23961=[""].join("\n");
var outline_f23_25_23961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708727\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053105\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5505100\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053108\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053160\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15044040\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062963\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053161\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807218\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053167\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9848865\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053163\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053110\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053141\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053116\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053117\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053147\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053146\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053150\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053111\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053112\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053114\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053115\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053162\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422185\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053165\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5505139\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053155\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053157\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8858|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/23/25973?source=related_link\">",
"      Efavirenz, tenofovir, and emtricitabine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/4/36937?source=related_link\">",
"      Efavirenz, tenofovir, and emtricitabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_25_23962="Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease";
var content_f23_25_23962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23962/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23962/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23962/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23962/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/25/23962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/25/23962/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/25/23962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and chronic graft-verus-host disease (GVHD) are multisystem disorders that are common complications of allogeneic hematopoietic cell transplant (HCT). GVHD occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GVHD has been classically divided into acute and chronic variants based upon the time of onset using a cutoff of 100 days. However, this conventional division has been challenged by the recognition that signs of acute and chronic GVHD may occur outside of these designated periods. This observation has led to the increased use of clinical findings, rather than a set time period, to differentiate between acute and chronic GVHD. The widely accepted National Institute of Health (NIH) consensus criteria for the diagnosis of GVHD include an overlap syndrome in which diagnostic or distinctive features of chronic GVHD and acute GVHD appear together [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations of chronic GVHD include skin involvement resembling lichen planus or the cutaneous manifestations of scleroderma; dry oral mucosa with ulcerations and sclerosis of the gastrointestinal tract; and a rising serum bilirubin concentration. In contrast, patients with acute GVHD commonly demonstrate a classic maculopapular rash; abdominal cramps with diarrhea; and a rising serum bilirubin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Clinical and histological manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical manifestations, diagnosis, and grading of chronic GVHD. The treatment of chronic GVHD and issues concerning acute GVHD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic GVHD can occur after previous or ongoing acute GVHD or in patients without a history of acute GVHD (eg, de novo disease). The exact incidence of chronic GVHD after allogeneic HCT is unknown. While chronic GVHD occurs in approximately 40 percent of allogeneic HCT recipient, reported incidence rates range from 6 to 80 percent, depending upon the presence of risk factors and the diagnostic criteria used [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. While risk factors for the development of GVHD have been identified, reliable estimates of GVHD incidence in various cohorts are not available due to variability in the identification, measurement, and documentation of chronic GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89544863\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the major risk factors for the development of chronic GVHD include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher degree of HLA mismatching",
"     </li>",
"     <li>",
"      Older age of donor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recipient",
"     </li>",
"     <li>",
"      Donor and recipient gender disparity (female donor to male recipient)",
"     </li>",
"     <li>",
"      Alloimmunization of the donor (history of pregnancy, transfusions)",
"     </li>",
"     <li>",
"      Source of stem cells (peripheral blood precursor cells [PBPC] rather than bone marrow or umbilical cord blood)",
"     </li>",
"     <li>",
"      Prior acute GVHD",
"     </li>",
"     <li>",
"      Administration of unirradiated donor buffy coat transfusions (eg, donor lymphocyte infusions)",
"     </li>",
"     <li>",
"      Previous splenectomy",
"     </li>",
"     <li>",
"      Cytomegalovirus seropositivity (donor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recipient)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less well established predictive factors include total body irradiation-containing regimens, second bone marrow infusions, preceding herpesvirus infection, the type of underlying malignancy, and the absence of blood transfusions administered prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/2,8,10,11\">",
"     2,8,10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H16#H16\">",
"     \"Sources of hematopoietic stem cells\", section on 'Relative efficacy of PBPC versus bone marrow'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of more than one of these risk factors increases the probability of developing chronic GVHD. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study evaluated the risk factors for chronic GVHD among 551 consecutive recipients of allogeneic bone marrow transplants [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/2\">",
"       2",
"      </a>",
"      ]. Among 34 analyzed variables, high recipient age, previous acute GVHD, female donor to male recipient, and a history of chronic myeloid leukemia were identified as significant risk factors for the development of chronic GVHD. At five years post-transplant, the incidence of chronic GVHD was 75, 68, 53, 29, and 9 percent among patients with four, three, two, one, and none of these four factors, respectively.",
"     </li>",
"     <li>",
"      In a study of 116 consecutive evaluable HLA-identical allogeneic PBPC transplants, the cumulative incidence of chronic GVHD was 57 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/12\">",
"       12",
"      </a>",
"      ]. On multivariate analysis, GVHD prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      was associated with a reduced risk of chronic GVHD (hazard ratio [HR] 0.35, 95% confidence interval [CI] 0.2-0.6), while prior acute GVHD was associated with an increased risk (HR 1.67, 95% CI: 1.0-2.8). The presence of high-risk chronic GVHD (ie, platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL)",
"      </span>",
"      had an adverse impact on overall mortality (HR 6.6, 95% CI 3.5-12.4) and treatment failure (ie, relapse or death without relapse; HR 5.2, 95% CI 2.9-9.4).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL AND HISTOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6074138\">",
"    <span class=\"h2\">",
"     Distribution of disease and definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin, liver, gastrointestinal tract, and lungs are the principal target organs involved in patients with chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This was illustrated in a prospective study of 458 patients with chronic GVHD that reported involvement in the following areas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin &mdash; 67 percent (see",
"      <a class=\"local\" href=\"#H6074276\">",
"       'Skin'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Mouth &mdash; 60 percent (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Gastrointestinal tract'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Liver &mdash; 52 percent (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Liver'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Lung &mdash; 50 percent (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Lung'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Eye &mdash; 48 percent (see",
"      <a class=\"local\" href=\"#H6074386\">",
"       'Eyes'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Joints and fascia &mdash; 48 percent (see",
"      <a class=\"local\" href=\"#H6225168\">",
"       'Musculoskeletal disease'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Gastrointestinal tract &mdash; 30 percent (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Gastrointestinal tract'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Genitalia &mdash; 12 percent (see",
"      <a class=\"local\" href=\"#H978026\">",
"       'Genitalia'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presenting symptoms are in some ways similar to those found in other well-established autoimmune syndromes. However, in chronic GVHD, there is not a uniform presentation, but rather a variable involvement of these and other organs. This variation makes clinical therapeutic studies difficult, since comparisons of responses may be different depending on the severity of involvement as well as the involved target organ.",
"   </p>",
"   <p>",
"    The NIH consensus criteria used to diagnose chronic GVHD classify manifestations as &ldquo;diagnostic&rdquo; or &ldquo;distinctive&rdquo; (",
"    <a class=\"graphic graphic_table graphicRef63007 \" href=\"UTD.htm?21/15/21757\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]. Diagnostic features are those that establish the diagnosis of chronic GVHD without need of further investigation. In contrast, distinctive features are seen in patients with chronic GVHD and are absent in patients with acute GVHD, but require further investigation to confirm the diagnosis. Diagnostic, distinctive, and other clinical manifestations of chronic GVHD are described in the following sections. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'NIH consensus criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with features of acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic GVHD are subclassified based upon the timing of presentation and the features present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classic acute GVHD",
"      </strong>",
"      &mdash; Cases present within 100 days of HCT and display features of acute GVHD. Features of chronic GVHD are absent.",
"     </li>",
"     <li>",
"      <strong>",
"       Persistent, recurrent, late onset acute GVHD",
"      </strong>",
"      &mdash; Cases present greater than 100 days post-HCT with features of acute GVHD. Features of chronic GVHD are absent.",
"     </li>",
"     <li>",
"      <strong>",
"       Classic chronic GVHD",
"      </strong>",
"      &mdash; Cases may present at any time post-HCT. Features of chronic GVHD are present. There are no features of acute GVHD.",
"     </li>",
"     <li>",
"      <strong>",
"       Overlap syndrome",
"      </strong>",
"      &mdash; Cases may present at any time post-HCT with features of both chronic GVHD and acute GVHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mucocutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucocutaneous manifestations of chronic GVHD include changes in the skin, nails, scalp and body hair, mouth, eyes, and genitalia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6074276\">",
"    <span class=\"h3\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin involvement is the most common clinical feature of chronic GVHD and is seen in approximately 67 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/15\">",
"     15",
"    </a>",
"    ]. Traditionally, chronic cutaneous GVHD has been classified as lichen planus-like or sclerotic (resembling scleroderma); however, many different clinical presentations of chronic GVHD are now recognized, reflecting a spectrum of epidermal and dermal (sclerotic) changes. Details regarding the cutaneous manifestations of chronic GVHD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link&amp;anchor=H733638#H733638\">",
"     \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Skin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, the onset of skin involvement may be heralded by generalized erythema, plaques, and waves of desquamation with continued underlying erythema. Affected patients often give a history of photoactivation. Alternating areas of hyperpigmentation and hypopigmentation are commonly observed. Without effective treatment, the affected skin may become progressively indurated and fixed to the underlying fascia. The epidermis becomes significantly atrophic with prominent poikiloderma, with some patients possessing localized lesions that resemble morphea. The skin may be hyperpigmented, hypopigmented,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hide-like, with the development of joint contractures similar to those observed with scleroderma.",
"   </p>",
"   <p>",
"    The following cutaneous findings can establish the presence of chronic GVHD without the need for further testing or evidence of other organ involvement (ie, diagnostic features) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Poikiloderma",
"      </strong>",
"      &mdash; A combination of atrophy, hypopigmentation, and hyperpigmentation in the skin usually appearing as patches with mottled pigmentation and telangiectasias (",
"      <a class=\"graphic graphic_picture graphicRef66942 \" href=\"UTD.htm?5/46/5858\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Lichen planus-like features",
"      </strong>",
"      &mdash; Erythematous to violaceous papules or plaques with a predilection for the dorsal hands and feet, forearms, and trunk (",
"      <a class=\"graphic graphic_picture graphicRef55336 \" href=\"UTD.htm?34/2/34851\">",
"       picture 2",
"      </a>",
"      ). Fine scale may be present.",
"     </li>",
"     <li>",
"      <strong>",
"       Sclerotic features",
"      </strong>",
"      &mdash; A cellulite-like rippled appearance of the skin due to thickening of the fibrous septae within fat, particularly on the medial arms and thighs (",
"      <a class=\"graphic graphic_picture graphicRef64464 \" href=\"UTD.htm?18/44/19151\">",
"       picture 3",
"      </a>",
"      ). Fascial involvement tends to occur late in the chronic period, and may lead to the appearance of prominent linear demarcations, often referred to as the &ldquo;groove sign,&rdquo; and contractures that limit range of motion (",
"      <a class=\"graphic graphic_picture graphicRef76298 \" href=\"UTD.htm?4/2/4130\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Morphea-like features",
"      </strong>",
"      &mdash; Firm, hyperpigmented, hypopigmented, or skin-colored plaques (",
"      <a class=\"graphic graphic_picture graphicRef52693 \" href=\"UTD.htm?3/63/4082\">",
"       picture 5",
"      </a>",
"      ). Affected skin often has a shiny appearance and demonstrates hair loss secondary to elimination of adnexal structures.",
"     </li>",
"     <li>",
"      <strong>",
"       Lichen sclerosis-like features",
"      </strong>",
"      &mdash; A dermatosis characterized by epidermal atrophy and superficial dermal fibrosis (",
"      <a class=\"graphic graphic_picture graphicRef74154 \" href=\"UTD.htm?26/37/27216\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depigmentation is seen in patients with chronic GVHD, but is not considered sufficient to establish an unequivocal diagnosis. Other features of chronic GVHD include sweat impairment, ichthyosis, keratosis pilaris, hypopigmentation, and hyperpigmentation. Skin changes seen in patients with both chronic and acute GVHD include erythema, maculopapular rash, and pruritus. The presence of these common features suggests the overlap subtype of chronic GVHD. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'NIH consensus criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6074386\">",
"    <span class=\"h3\">",
"     Eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 to 60 percent of adult patients with chronic GVHD will have involvement of their eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In a prospective study of 387 patients with chronic GVHD, 69 percent of patients reported eye-related symptoms, while clinicians documented eye involvement in 52 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/16\">",
"     16",
"    </a>",
"    ]. Symptoms can range from mild dry eyes to eye pain and loss of vision.",
"   </p>",
"   <p>",
"    In a retrospective analysis of 429 patients with chronic GVHD, visual acuity of",
"    <span class=\"nowrap\">",
"     &ge;20/40",
"    </span>",
"    in at least one eye was seen in 422 patients (98.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/17\">",
"     17",
"    </a>",
"    ]. Ocular findings on examination included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aqueous tear deficiency (Schirmer score &le;5 mm) &mdash; 53.4 percent",
"     </li>",
"     <li>",
"      Cataracts &mdash; 39.4 percent",
"     </li>",
"     <li>",
"      Corneal epithelial staining &mdash; 33.6 percent",
"     </li>",
"     <li>",
"      Conjunctival hyperemia &mdash; 10.5 percent",
"     </li>",
"     <li>",
"      Chemosis &mdash; 3 percent",
"     </li>",
"     <li>",
"      Corneal epithelial sloughing, conjunctival subepithelial fibrosis, and symblepharon formation &mdash; &lt;1 percent each",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these factors, only the presence of cataracts was a risk factor for developing impairment in visual acuity",
"    <span class=\"nowrap\">",
"     (20/50",
"    </span>",
"    or worse). This suggests that, while chronic GVHD involves the eyes in the majority of patients, severe eye involvement is uncommon.",
"   </p>",
"   <p>",
"    There are no diagnostic signs of eye involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]. Distinctive signs include new onset dry, gritty, painful eyes; cicatricial conjunctivitis; keratoconjunctivitis sicca; or confluent areas of punctate keratopathy. Other features include photophobia, periorbital hyperpigmentation, and blepharitis (erythema of the eyelids with edema). While new ocular sicca documented by a low Schirmer score (&le;5 mm) or new onset of keratoconjunctivitis by slit-lamp examination is not diagnostic on its own, these features confirm eye involvement in patients with diagnostic manifestations of chronic GVHD in another organ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6074283\">",
"    <span class=\"h3\">",
"     Hair and nails",
"    </span>",
"    &nbsp;&mdash;&nbsp;While patients with chronic GVHD commonly have changes in their hair and nails, none is diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]. Distinctive nail signs include dystrophy (",
"    <a class=\"graphic graphic_picture graphicRef71229 \" href=\"UTD.htm?28/42/29345\">",
"     picture 7",
"    </a>",
"    ), longitudinal ridging, splitting, or brittle features; oncolysis; pterygium unguis; and nail loss (usually symmetric and affects most nails). Distinctive findings in the scalp and body hair include new onset of scarring or nonscarring scalp alopecia (after recovery from chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy); scaling; and papulosquamous lesions. Other findings include premature gray hair and thinning scalp hair, which is typically patchy, coarse, or dull. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link&amp;anchor=H733454#H733454\">",
"     \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Hair disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link&amp;anchor=H733461#H733461\">",
"     \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Nail disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H978026\">",
"    <span class=\"h3\">",
"     Genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecological manifestations, such as vaginal inflammation and stenosis, have been observed in patients with chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. The exact incidence is unknown and reported rates range from 11 to 48 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. Symptoms include vaginal dryness, dyspareunia, itching, burning, pain to touch, loss of libido, and amenorrhea.",
"   </p>",
"   <p>",
"    Findings on gynecologic examination that can establish the presence of chronic GVHD without the need for further testing or evidence of other organ involvement (ie, diagnostic features) are lichen planus-like features, vaginal scarring, or stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]. Other distinctive, but not diagnostic, signs are erosions, fissures, and ulcers.",
"   </p>",
"   <p>",
"    In a single center study of 32 patients with genital chronic GVHD, 23 patients (72 percent) had involvement of other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/20\">",
"     20",
"    </a>",
"    ]. Most patients complained about vaginal dryness, and approximately one-third had dyspareunia or a sensation of vaginal narrowing with impairment in sexual activity. In approximately half of patients, findings on examination were limited to generalized erythema and edema of the vulva, mucosal paleness, reticulated leukokeratosis, or erythema and tenderness on light pressure over the openings of Skene&rsquo;s",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Bartholin&rsquo;s ducts. The remainder had more severe disease including erosions, fissures, and vaginal stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately half of patients with chronic GVHD have some involvement of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/15\">",
"     15",
"    </a>",
"    ]. Often liver involvement is manifested as liver function test abnormalities without other major complications. The liver function tests are most consistent with those of cholestasis, with elevations in the serum alkaline phosphatase, ALT or AST, and bilirubin concentrations. There are no signs that are diagnostic or distinctive and the same liver findings occur in patients with acute and chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]. Liver biopsies are performed to confirm involvement when isolated hepatic GVHD is suspected. Biopsies variably showing lobular hepatitis, chronic persistent hepatitis, chronic active hepatitis, and a reduction or absence of small bile ducts with cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In most patients, the pathophysiology is suggestive of that observed with primary biliary cirrhosis, including biliary cell necrosis and basement membrane thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/25\">",
"     25",
"    </a>",
"    ]. In all cases, infection, drug effects, malignancy, or other causes must be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal tract is involved in the majority of patients with chronic GVHD. In a prospective study, oral lesions were seen in approximately 60 percent of patients and involvement of other areas of the gastrointestinal tract was present in 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oral mucosa is commonly dry, often resulting in pain secondary to ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/5,15,26\">",
"     5,15,26",
"    </a>",
"    ]. Findings on examination of the oral cavity that can establish the presence of chronic GVHD without the need for further testing or evidence of other organ involvement (ie, diagnostic features) are lichen-type features, hyperkeratotic plaques, or restriction of the mouth opening from sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. Other signs include xerostomia, mucocele, mucosal atrophy, pseudomembranes, ulcers, gingivitis, mucositis, erythema, and pain. Importantly, gingivitis, mucositis, erythema, and pain may be seen in both acute and chronic GVHD and, when present with other features of chronic GVHD, are used to designate the overlap subtype of chronic GVHD. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'NIH consensus criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with chronic GVHD may also have involvement of the esophagus, resulting in dysphagia, painful ulcers, and gradual weight loss. Findings on radiography may include webs, ring-like narrowing, and a tapering structure of the mid and upper esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/28\">",
"     28",
"    </a>",
"    ]. The presence of an esophageal web and strictures or stenosis in the upper to mid third of the esophagus is diagnostic of chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with small bowel and colonic involvement, common symptoms and signs include anorexia, nausea, vomiting, chronic diarrhea, malabsorption, weight loss, and failure to thrive (usually in infants and children). These symptoms can be seen in acute GVHD and the overlap subtype of chronic GVHD. Chronic GVHD can also result in exocrine pancreatic insufficiency.",
"   </p>",
"   <p>",
"    Endoscopy is commonly performed to investigate gastrointestinal tract involvement. Findings on endoscopy are variable and range from loss of vascular markings",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    focal mild erythema to severe erythema, edema, exudates, erosions, and ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/29\">",
"     29",
"    </a>",
"    ]. Biopsy specimens may demonstrate increased crypt apoptosis (grade 1), apoptosis with crypt abscesses (grade 2), individual crypt necrosis (grade 3), and total denudation of areas of mucosa (grade 4) (",
"    <a class=\"graphic graphic_picture graphicRef86936 \" href=\"UTD.htm?17/50/18215\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86937 \" href=\"UTD.htm?17/6/17511\">",
"     picture 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary involvement is present in approximately half of patients with chronic GVHD and may manifest as obstructive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    restrictive changes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/15,31\">",
"     15,31",
"    </a>",
"    ]. While a clinical diagnosis of bronchiolitis obliterans is suggestive of chronic GVHD, pathologic evidence of bronchiolitis obliterans is diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, organizing pneumonia (also called bronchiolitis obliterans organizing pneumonia, BOOP) is seen in both acute and chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With bronchiolitis obliterans, there is typically a temporal evolution of symptoms and signs. Initially, patients are asymptomatic with impairments seen only on pulmonary function tests. Early symptoms are generally mild dyspnea on exertion or dry and non-productive cough. Symptoms may progress to significant dyspnea on exertion, decreased exercise tolerance, and non-productive cough. Pulmonary involvement can ultimately progress to oxygen dependency, immobility, and death related to pulmonary infections. This is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A clinical diagnosis of bronchiolitis obliterans is made in a HCT recipient when",
"    <strong>",
"     all",
"    </strong>",
"    of the following are met [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forced expiratory volume in 1 second",
"      <span class=\"nowrap\">",
"       (FEV1)/forced",
"      </span>",
"      vital capacity (FVC) ratio &lt;0.7",
"      <strong>",
"       and",
"      </strong>",
"      FEV1 &lt;75 percent of predicted.",
"     </li>",
"     <li>",
"      Evidence of air trapping or small airway thickening or bronchiectasis on high resolution chest computed tomography, residual volume &gt;120 percent, or pathologic confirmation of constrictive bronchiolitis.",
"     </li>",
"     <li>",
"      Absence of infection in the respiratory tract, documented with investigations directed by clinical symptoms.",
"     </li>",
"     <li>",
"      On histology, the small airways are destroyed and fibrous obliteration of the lumen and the bronchioles can be observed with granulation tissue frequently extending into the alveolar ducts. This histologic pattern is also seen as a manifestation of chronic lung transplant rejection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link&amp;anchor=H2#H2\">",
"       \"Chronic lung transplant rejection: Bronchiolitis obliterans\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6225168\">",
"    <span class=\"h2\">",
"     Musculoskeletal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle-related complications are seen in up to 50 percent of patients with chronic GVHD, often presenting several months to many years after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/15\">",
"     15",
"    </a>",
"    ]. Signs that are common, but not specific, include edema, muscle cramps, arthralgia, and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. The two most notable musculoskeletal findings are fasciitis and myositis that resemble autoimmune eosinophilic fasciitis and idiopathic polymyositis, respectively. Retrospective analyses have reported these complications in less than 5 percent of patients undergoing allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical and histologic findings depend upon the type of disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fasciitis",
"      </strong>",
"      &mdash; Fasciitis manifests clinically as limitations in joint mobility and skin changes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/38\">",
"       38",
"      </a>",
"      ]. There is typically a temporal evolution of skin findings. Initially, there may be marked, nonpitting edema of the extremities. With progression of the disease, the swelling resolves and is replaced by symmetrical induration with puckering that gives the skin the texture of orange peel (peau d&rsquo;orange). Contractures and joint stiffness are also observed resulting in limited range of joint motion (",
"      <a class=\"graphic graphic_picture graphicRef76298 \" href=\"UTD.htm?4/2/4130\">",
"       picture 4",
"      </a>",
"      ). Magnetic resonance imaging (MRI) shows high intensity in muscle in fat suppressed T2 weighted images. Biopsy is often deferred due to concerns regarding the risk of impaired wound healing. When a biopsy is performed, histology demonstrates lymphocytic infiltration, edema, and fibrosis in the fascia and subcutaneous septa. The infiltration is diffuse and it often extends into the subcutaneous fat and pericapillary space, but usually spares the muscle itself. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8360?source=see_link\">",
"       \"Eosinophilic fasciitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Myositis",
"      </strong>",
"      &mdash; Myositis manifests clinically as weakness with or without myalgias [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/33,37\">",
"       33,37",
"      </a>",
"      ]. The muscle weakness is described as moderate to severe symmetrical weakness of the proximal muscles, the neck flexors,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      limb girdle. Involvement of the muscles of the upper esophagus, pharynx, respiratory system, and heart are rare. Serum creatine kinase is usually 5 to 50 times the upper limit of normal, but may be within normal limits early in the disease process. Elevations in other enzymes, such as lactate dehydrogenase, aldolase, and aminotransferases are also common. Autoantibodies directed against the nucleus, smooth muscle cells, or mitochondria may be present. Electromyography (EMG) is usually abnormal and demonstrates findings consistent with an inflammatory myopathy (eg, fibrillation potentials, positive sharp waves, short-duration and small amplitude motor unit action potentials, and full interference patterns in weak muscles). Biopsy is necessary to confirm involvement. Histopathology demonstrates the degeneration, necrosis and regeneration of muscle fibers and infiltrates of inflammatory cells of donor origin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fasciitis or joint contractors found on musculoskeletal examination can establish the presence of chronic GVHD without the need for further testing or evidence of other organ involvement (ie, diagnostic features) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6225507\">",
"    <span class=\"h2\">",
"     Hematopoietic and immune",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not diagnostic, patients with chronic GVHD commonly have laboratory abnormalities reflecting changes in the hematopoietic and immune systems. These findings include thrombocytopenia, eosinophilia, lymphopenia,",
"    <span class=\"nowrap\">",
"     hypo/hypergammaglobulinemia,",
"    </span>",
"    and autoantibodies. In one study of 138 patients with chronic GVHD, eosinophilia (range 0.5 to",
"    <span class=\"nowrap\">",
"     4/4",
"    </span>",
"    x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    and thrombocytopenia were present in 44 and 11 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/39\">",
"     39",
"    </a>",
"    ]. In another study, thrombocytopenia was seen in 15 percent of patients with chronic GVHD and predicted worse survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6225514\">",
"    <span class=\"h3\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies found in patients with chronic GVHD are similar to those observed in systemic lupus erythematosus and other rheumatologic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. One study, for example, screened the sera of 32 transplant recipients for autoantibodies, 20 of whom had chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/44\">",
"     44",
"    </a>",
"    ]. Antinucleolar antibodies were observed in 12 patients with chronic GVHD and none in those without GVHD. The emergence of autoantibody formation was concurrent with the onset of clinical symptoms of GVHD. A high frequency of antimitochondrial antibodies (80 percent) was found in another small series of patients with GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     &nbsp;T cells",
"    </strong>",
"    &mdash; Chronic GVHD leads to marked immunodeficiency due to both direct immunosuppressive effects and the consequences of the agents administered to treat the disease. Since chronic GVHD also causes a delay in the recovery of immune function, patients remain immunodeficient as long as the disease is active [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/46\">",
"     46",
"    </a>",
"    ]. Dysregulation of T and B lymphocyte control may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/47\">",
"     47",
"    </a>",
"    ]. Because of the profound immunosuppression observed with this disorder, recurrent infections occur in almost all affected patients. These complications account for most of the morbidity and mortality associated with chronic GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6225565\">",
"    <span class=\"h3\">",
"     IgA deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA deficiency occurs in many patients following allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], and may be related to the development of acute and chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In a study of 134 HCT recipients, for example, those with chronic GVHD had significantly lower IgA levels than patients without the disease at one and two years post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/51\">",
"     51",
"    </a>",
"    ]. However, IgA deficiency alone may not have an independent role in the development of chronic GVHD since normal IgA levels were found in all patients with chronic GVHD who did not have a history of acute GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other uncommon clinical manifestations that can occur in patients with chronic GVHD include polyserositis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/38\">",
"     38",
"    </a>",
"    ], polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/34,52\">",
"     34,52",
"    </a>",
"    ], myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/53\">",
"     53",
"    </a>",
"    ], large to medium vessel vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/33\">",
"     33",
"    </a>",
"    ], demyelinating disease of the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/33\">",
"     33",
"    </a>",
"    ], immune-mediated encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/33\">",
"     33",
"    </a>",
"    ], peripheral neuropathy, cardiac conduction abnormalities, cardiomyopathy, and the nephrotic syndrome due to membranous nephropathy, or less commonly, minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/54-58\">",
"     54-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polyserositis can manifest with pericardial or pleural effusions, ascites, and facial, scrotal, or limb edema [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/38\">",
"     38",
"    </a>",
"    ]. The sicca syndrome in patients with chronic GVHD is similar to that found in those with the disorder due to other autoimmune diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H979753\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic GVHD should be considered in any patient who has undergone allogeneic hematopoietic cell transplantation (HCT). Chronic GVHD can occur at any time point in the post-HCT setting and screening for signs and symptoms of chronic GVHD should be incorporated into the long-term follow-up of transplant survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/59\">",
"     59",
"    </a>",
"    ]. An instructional video on how to perform a comprehensive chronic GVHD assessment is available from the",
"    <a class=\"external\" href=\"file://www.fhcrc.org/en/labs/clinical/projects/gvhd.html\">",
"     Fred Hutchinson Cancer Research Center",
"    </a>",
"    . Chronic GVHD can be readily made on clinical grounds in the patient who presents with the classic features of skin involvement, manifestations of gastrointestinal involvement, and a rising serum bilirubin concentration. In many cases, however, the diagnosis is less straightforward and competing causes for isolated abnormalities must be considered and excluded.",
"   </p>",
"   <p>",
"    Since the clinical diagnosis is one of exclusion, histologic confirmation is often necessary to corroborate a clinical impression of possible chronic GVHD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic GVHD is commonly detected pathologically via a 4 mm punch skin biopsy, which secures a full dermal thickness specimen including subcutaneous fat. A biopsy of sun-exposed forearm areas may reveal diagnostic changes, even in the absence of a rash. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link&amp;anchor=H832193#H832193\">",
"       \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Skin biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral biopsies are also very effective in detecting the presence of chronic GVHD.",
"     </li>",
"     <li>",
"      A transjugular liver biopsy may be necessary in patients with isolated liver abnormalities. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Liver'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A lung biopsy demonstrating pathologic evidence of bronchiolitis obliterans can be diagnostic. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lung'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The need for biopsy in a specific patient and type of biopsy performed is dependent upon the signs and symptoms present. The National Institutes of Health (NIH) consensus criteria described in the following section provide guidance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     NIH consensus criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic GVHD is diagnosed using criteria created through the NIH consensus development project and published in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1,60\">",
"     1,60",
"    </a>",
"    ]. These NIH consensus criteria are used by most transplant centers in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/61\">",
"     61",
"    </a>",
"    ]. The following principles of diagnosis apply [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic GVHD can occur at any time point following allogeneic hematopoietic cell transplantation (HCT).",
"     </li>",
"     <li>",
"      In most cases, chronic GVHD is a diagnosis of exclusion and other possible causes of clinical symptoms must be considered. (See",
"      <a class=\"local\" href=\"#H6074145\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The NIH consensus criteria have identified signs and symptoms of chronic GVHD that are diagnostic or distinctive (",
"      <a class=\"graphic graphic_table graphicRef63007 \" href=\"UTD.htm?21/15/21757\">",
"       table 1",
"      </a>",
"      ). &ldquo;Diagnostic features&rdquo; are those that establish the diagnosis of chronic GVHD without need of further investigation (eg, poikiloderma, esophageal web). In contrast, &ldquo;distinctive features&rdquo; are seen in patients with chronic GVHD and are absent in patients with acute GVHD, but require further investigation to confirm the diagnosis (eg, skin depigmentation, keratoconjunctivitis sicca). &nbsp;",
"     </li>",
"     <li>",
"      To make a diagnosis of chronic GVHD, at least one diagnostic clinical sign of chronic GVHD must be present",
"      <strong>",
"       or",
"      </strong>",
"      at least one distinctive manifestation must be confirmed by pertinent biopsy or other relevant tests (eg, Schirmer test) in the same or another organ.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients diagnosed with chronic GVHD are then subclassified based upon the presence or absence of features of acute GVHD into one of two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classic chronic GVHD",
"      </strong>",
"      &mdash; Features of chronic GVHD are present without signs or symptoms of acute GVHD.",
"     </li>",
"     <li>",
"      <strong>",
"       Overlap syndrome",
"      </strong>",
"      &mdash; Features of both chronic GVHD and acute GVHD are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Features of acute GVHD seen in the overlap syndrome include changes in the skin (skin erythema, maculopapular rash, pruritus), mouth (gingivitis, mucositis, oral erythema, oral pain), gastrointestinal symptoms (anorexia, nausea, vomiting, diarrhea, weight loss, failure to thrive), liver dysfunction (elevations in bilirubin, alkaline phosphatase, ALT, or AST), and organizing pneumonia (also called bronchiolitis obliterans organizing pneumonia, BOOP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6074145\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, chronic GVHD is a diagnosis of exclusion and other possible causes of clinical symptoms must be considered. The differential diagnosis depends upon the presenting signs and symptoms of chronic GVHD. Most alternative diagnoses can be excluded on biopsy of the involved tissue.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Skin involvement",
"      </strong>",
"      &mdash; The differential diagnosis of patients presenting with signs and symptoms of GVHD of the skin includes lichen planus, lichen sclerosus, morphea, systemic sclerosis, eosinophilic fasciitis, and other causes of poikiloderma. Findings on gynecologic examination may resemble postmenopausal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/20\">",
"       20",
"      </a>",
"      ]. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link&amp;anchor=H733020#H733020\">",
"       \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Differential diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"       \"Clinical manifestations and diagnosis of menopause\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Liver involvement",
"      </strong>",
"      &mdash; The differential diagnosis of hepatic GVHD includes other causes of cholestasis, including infection, drug effects, and malignancy (",
"      <a class=\"graphic graphic_table graphicRef57570 \" href=\"UTD.htm?37/16/38156\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef71068 \" href=\"UTD.htm?38/58/39852\">",
"       table 3",
"      </a>",
"      ). At times a specific diagnosis is difficult without biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link\">",
"       \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"       \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Gastrointestinal tract",
"      </strong>",
"      &mdash; The differential diagnosis of GVHD of the gastrointestinal tract includes other causes of nausea, vomiting, diarrhea, and weight loss. These include infectious causes (eg, C difficile infection, CMV reactivation), drug effects, chemoradiation toxicity, inflammatory diarrhea, short bowel syndrome, peptic ulcer disease, neoplasms, systemic disease (eg, diabetes mellitus). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"       \"Approach to the adult with chronic diarrhea in developed countries\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=see_link\">",
"       \"Approach to the adult with nausea and vomiting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lung",
"      </strong>",
"      &mdash; The differential diagnosis of pulmonary GVHD includes other causes of restrictive and obstructive lung function. These include infections (eg, cytomegalovirus, toxoplasmosis), interstitial lung disease, granulomatous disease (eg, sarcoidosis), and diffuse alveolar hemorrhage. An approach to the patient with respiratory symptoms post-HCT is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link&amp;anchor=H14112523#H14112523\">",
"       \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Approach to the patient with respiratory symptoms or signs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Musculoskeletal disease",
"      </strong>",
"      &mdash; The differential diagnosis of musculoskeletal involvement of GVHD includes other causes of fasciitis and myositis, including dermatomyositis, inclusion body myositis, and other causes of rhabdomyolysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"       \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=see_link\">",
"       \"Causes of rhabdomyolysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A continuum of clinical findings may be observed in patients with acute and chronic GVHD, as both disorders commonly affect similar organs, principally the skin, liver, and gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the target organs affected by, and the clinical and histologic features associated with, chronic GVHD may differ from those observed with acute disease. As an example, autoimmune phenomena, such as autoantibody formation, are more common with chronic GVHD. Clinical aspects of chronic GVHD may also mimic features frequently observed with systemic lupus erythematosus, scleroderma, sicca syndrome, eosinophilic fasciitis, rheumatoid arthritis, and primary biliary sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/62\">",
"     62",
"    </a>",
"    ]. Importantly, diagnostic or distinctive signs of chronic GVHD must be absent in order to make the diagnosis of acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with signs or symptoms seen in both entities are considered to have the overlap subtype of chronic GVHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND GRADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systems for grading chronic GVHD have been developed. None has been compared with the others, although initial data suggest that they predict prognosis. In addition, these scoring systems allow for the detailed review and documentation of organ involvement. Clinicians should incorporate detailed documentation to avoid relying on their memory of organ involvement between visits. A few institutions incorporate digital photography into their records.",
"   </p>",
"   <p>",
"    In a study of 2900 allogeneic transplants from the International Bone Marrow Transplant Registry and 553 from the National Marrow Donor Program, the presence of chronic GVHD was similarly associated with a higher treatment-related mortality (relative risk [RR] 1.8 to 2.8 for three different comparison groups; 95% CI 1.3-4.1), but a lower rate of disease relapse (RR 0.5 to 0.6 for the three comparison groups; 95% CI 0.3-1.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/63\">",
"     63",
"    </a>",
"    ]. Survival and disease-free survival of the most favorable chronic GVHD group in each of the three comparison groups were similar to, or better than, those of patients without chronic GVHD, suggesting an important link between the graft-versus-host and the graft-versus-tumor phenomena. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H4#H4\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Identical twin donors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210172026\">",
"    <span class=\"h2\">",
"     NIH consensus criteria for GVHD severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A scoring system for chronic GVHD severity was created at a consensus conference supported by the National Institutes of Health (NIH) in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NIH GVHD scoring system includes information on the number of organs or sites involved and the severity within each affected organ (eg, skin, mouth, eyes, gastrointestinal tract, liver, lungs,",
"    <span class=\"nowrap\">",
"     joints/fascia,",
"    </span>",
"    and genital tract) (",
"    <a class=\"graphic graphic_figure graphicRef69017 \" href=\"UTD.htm?7/2/7209\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"     1",
"    </a>",
"    ]. Organ specific severity is scored from 0 to 3 with higher scores reflecting more severe disease. Based upon this information, the overall severity is scored as mild, moderate, or severe:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild &mdash; Involves two or fewer",
"      <span class=\"nowrap\">",
"       organs/sites",
"      </span>",
"      with no clinically significant functional impairment",
"     </li>",
"     <li>",
"      Moderate &mdash; Involves three or more",
"      <span class=\"nowrap\">",
"       organs/sites",
"      </span>",
"      with no clinically significant functional impairment or at least one",
"      <span class=\"nowrap\">",
"       organ/site",
"      </span>",
"      with clinically significant functional impairment, but no major disability",
"     </li>",
"     <li>",
"      Severe &mdash; Major disability caused by chronic GVHD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are being collected prospectively in an attempt to validate these criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/64\">",
"     64",
"    </a>",
"    ]. Initial results support the use of this grading system:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a report of the initial 298 adult patients enrolled in a prospective study, chronic GVHD severity was mild, moderate, and severe in 10, 59, and 31 percent of patients at diagnosis, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/65\">",
"       65",
"      </a>",
"      ]. Patients with a higher severity score had a significantly higher rate of non-relapse mortality and shorter survival. Overall survival at two years was 97, 86, and 62 percent for patients with mild, moderate, and severe chronic GVHD, respectively. An additional report suggested that moderate to severe chronic GVHD, as defined by these criteria, is associated with significantly decreased quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In an expanded cohort from this multicenter, prospective, longitudinal study that included 387 patients with chronic GVHD, the NIH eye score correlated with the perceived change in severity, in either direction, by both clinicians and patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Further expansion of this cohort to include 458 patients with chronic GVHD validated the prognostic value of the composite skin score contained within the NIH consensus criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/15\">",
"       15",
"      </a>",
"      ]. Of the 285 patients who had skin involvement at enrollment, composite skin scores of 1, 2, and 3 were identified in 37, 39, and 24 percent, respectively. Changes in scores over time correlated with the perceived change in severity, in either direction, by both clinicians and patients. At a median follow-up of 18.8 months, rates of overall survival at two years correlated with skin scores being 86, 83, 81, and 69 percent among patients with scores of 0, 1, 2, and 3, respectively. Corresponding rates of non-relapse mortality at two years were 10, 13, 15, and 30 percent. A worsening score at six months was associated with increased mortality (hazard ratio [HR] 4.7, 95% CI 0.9-25.1) and higher non-relapse mortality (HR 7.2, 95% CI 1.2-43.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210172246\">",
"    <span class=\"h2\">",
"     CIBMTR chronic GVHD risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Center for International Blood and Marrow Transplant Research (CIBMTR) has proposed a chronic GVHD risk score based upon the retrospective evaluation of 5343 patients with chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/67\">",
"     67",
"    </a>",
"    ]. A chronic GVHD risk score was developed using 10 variables measured at the time of chronic GVHD diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age of recipient at transplantation (&lt;29 years = 0 points; 30 to 59 years = 1 point; &gt;60 years = 2 points)",
"     </li>",
"     <li>",
"      Prior acute GVHD (none = 0 points; present = 1 point)",
"     </li>",
"     <li>",
"      Time from transplant to development of chronic GVHD (&ge;5 months = 0 points; &lt;5 months = 1 point)",
"     </li>",
"     <li>",
"      Serum bilirubin at diagnosis of chronic GVHD (&le;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      = 0 points; &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      = 2 points)",
"     </li>",
"     <li>",
"      Karnofsky performance score (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 4",
"      </a>",
"      ) (&ge;80 = 0 points; &lt;80 = 1 point)",
"     </li>",
"     <li>",
"      Platelet count (&ge;100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      = 0 points; &lt;100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      = 1 point)",
"     </li>",
"     <li>",
"      Type of donor (HLA-identical",
"      <span class=\"nowrap\">",
"       sibling/well-matched",
"      </span>",
"      or partially matched unrelated donor = 0 points; other = 1 point)",
"     </li>",
"     <li>",
"      Disease status at transplant (early = 0 points; intermediate = 1 point; advanced = 2 points)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Donor/recipient",
"      </span>",
"      sex mismatch",
"      <span class=\"nowrap\">",
"       (female/male",
"      </span>",
"      = 1 point; others = 0 points)",
"     </li>",
"     <li>",
"      GVHD prophylaxis (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      combination = 0 points; other = 1 point)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study, early disease included patients undergoing transplant in first remission of acute leukemia, first chronic phase of chronic myelogenous leukemia (CML), or for myelodysplastic syndromes (MDS) with refractory anemia or refractory anemia with ring sideroblasts. Intermediate disease included those with second or later complete remission for acute leukemia, second or later chronic phase or accelerated phase for CML. Advanced disease included patients in relapse or primary induction failure for acute leukemia or blast crisis for CML or MDS with refractory anemia with excess blasts or excess blasts in transformation. Using these variables, patients could be divided into six risk groups (RG) based upon overall risk score with associated rates of overall survival (OS) and non-relapse mortality (NRM) at five years:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      RG1 &mdash; 0 to 2 points; 91 percent OS; 5 percent NRM",
"     </li>",
"     <li>",
"      RG2 &mdash; 3 to 6 points; 67 percent OS; 20 percent NRM",
"     </li>",
"     <li>",
"      RG3 &mdash; 7 to 8 points; 51 percent OS; 33 percent NRM",
"     </li>",
"     <li>",
"      RG4 &mdash; 9 to 10 points; 40 percent OS; 43 percent NRM",
"     </li>",
"     <li>",
"      RG5 &mdash; 11 points; 21 percent OS; 63 percent NRM",
"     </li>",
"     <li>",
"      RG6 &mdash; &gt;12 points; 4 percent OS; 67 percent NRM",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While requiring validation in another patient cohort, this score is attractive because it incorporates several known risk factors and is relatively easy to apply clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Johns Hopkins grading system",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proposed grading system for assessing long-term prognosis in chronic GVHD (eg, non-relapse mortality, GVHD-specific survival), has been tested retrospectively in several transplantation centers, using the following three adverse prognostic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin involvement &gt;50 percent of body surface area",
"     </li>",
"     <li>",
"      Progressive-type onset of chronic GVHD",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prospective validation of this grading system, along with its relation to other adverse features (eg, Karnofsky performance score, prior occurrence of acute GVHD, serum bilirubin, other transplantation-associated risk factors) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/25/23962/abstract/68,70\">",
"     68,70",
"    </a>",
"    ] will be required before it can be used routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H979161\">",
"    <span class=\"h2\">",
"     Limited versus extensive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, chronic GVHD has been graded as either limited or extensive based upon the clinical severity and target organs affected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited disease is characterized by localized skin involvement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evidence of hepatic dysfunction.",
"     </li>",
"     <li>",
"      Extensive disease presents either with generalized skin involvement, or with localized skin involvement or hepatic dysfunction plus",
"      <strong>",
"       at least one",
"      </strong>",
"      of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Liver histology showing chronic progressive hepatitis, bridging necrosis, or cirrhosis",
"     </li>",
"     <li>",
"      Involvement of the eye (Schirmer's test with less than 5 mm wetting) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"       \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Involvement of minor salivary glands or oral mucosa (as demonstrated on labial or mucosal biopsy specimen)",
"     </li>",
"     <li>",
"      Involvement of any other target organ",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While many clinicians continue to use this grading system for GVHD, it was created based upon a small cohort of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25783453\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient.",
"     </li>",
"     <li>",
"      Chronic GVHD occurs in more than 50 percent of long-term survivors of HLA-identical sibling transplants. It can occur after previous or ongoing acute GVHD or in patients without a history of acute GVHD (eg, de novo disease). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The skin, liver, gastrointestinal tract, and lungs are the principal target organs involved in patients with chronic GVHD:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Skin involvement most closely resembles lichen planus or the cutaneous manifestations of scleroderma. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mucocutaneous manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Liver involvement is suggested by elevations in the serum alkaline phosphatase and bilirubin concentrations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Liver'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal involvement often manifests as dry oral mucosa with ulcerations, dysphagia with weight loss, chronic diarrhea and malabsorption. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Gastrointestinal tract'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary involvement can result in bronchiolitis obliterans. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lung'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other clinical manifestations include changes in the eye and female genitalia, thrombocytopenia, sicca syndrome, polymyositis, myasthenia gravis, nephrotic syndrome or minimal change disease, and vaginal inflammation and stenosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of chronic GVHD can be readily made on clinical grounds in the patient who presents with the classic features of skin involvement, manifestations of gastrointestinal involvement, and a rising serum bilirubin concentration. In many cases, however, the diagnosis is less straightforward and histologic confirmation is often necessary to corroborate a clinical impression of possible chronic GVHD. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The National Institute of Health (NIH) consensus criteria have identified signs and symptoms of chronic GVHD that are diagnostic or distinctive (",
"      <a class=\"graphic graphic_table graphicRef63007 \" href=\"UTD.htm?21/15/21757\">",
"       table 1",
"      </a>",
"      ). &ldquo;Diagnostic features&rdquo; are those that establish the diagnosis of chronic GVHD without need of further investigation (eg, poikiloderma, esophageal web). In contrast, &ldquo;distinctive features&rdquo; are seen in patients with chronic GVHD and are absent in patients with acute GVHD, but require further investigation to confirm the diagnosis (eg, skin depigmentation, keratoconjunctivitis sicca). &nbsp;",
"     </li>",
"     <li>",
"      To make a diagnosis of chronic GVHD, at least one diagnostic clinical sign of chronic GVHD must be present",
"      <strong>",
"       or",
"      </strong>",
"      at least one distinctive manifestation must be confirmed by pertinent biopsy or other relevant tests (eg, Schirmer test) in the same or another organ.",
"     </li>",
"     <li>",
"      In most cases, chronic GVHD is a diagnosis of exclusion and other possible causes of clinical symptoms must be considered. The differential diagnosis depends upon the presenting signs and symptoms of chronic GVHD. Most alternative diagnoses can be excluded on biopsy of the involved tissue. (See",
"      <a class=\"local\" href=\"#H6074145\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several systems for grading chronic GVHD have been developed. None has been compared with the others, although initial data suggest that they predict prognosis. Of these, the NIH GVHD scoring system is the only one that has been prospectively validated. (See",
"      <a class=\"local\" href=\"#H210172026\">",
"       'NIH consensus criteria for GVHD severity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/1\">",
"      Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/2\">",
"      Carlens S, Ringd&eacute;n O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998; 22:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/3\">",
"      Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/4\">",
"      Ochs LA, Miller WJ, Filipovich AH, et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994; 13:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/5\">",
"      Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/6\">",
"      Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/7\">",
"      Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004; 125:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/8\">",
"      Ozawa S, Nakaseko C, Nishimura M, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol 2007; 137:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/9\">",
"      Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117:3214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/10\">",
"      Bolger GB, Sullivan KM, Storb R, et al. Second marrow infusion for poor graft function after allogeneic marrow transplantation. Bone Marrow Transplant 1986; 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/11\">",
"      Bostr&ouml;m L, Ringd&eacute;n O, Jacobsen N, et al. A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors--acute graft-versus-host disease, and splenectomy. Transplantation 1990; 49:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/12\">",
"      Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/13\">",
"      Bhushan V, Collins RH Jr. Chronic graft-vs-host disease. JAMA 2003; 290:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/14\">",
"      Joseph RW, Couriel DR, Komanduri KV. Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. J Support Oncol 2008; 6:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/15\">",
"      Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 2012; 120:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/16\">",
"      Inamoto Y, Chai X, Kurland BF, et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology 2012; 119:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/17\">",
"      Allan EJ, Flowers ME, Lin MP, et al. Visual acuity and anterior segment findings in chronic graft-versus-host disease. Cornea 2011; 30:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/18\">",
"      Corson SL, Sullivan K, Batzer F, et al. Gynecologic manifestations of chronic graft-versus-host disease. Obstet Gynecol 1982; 60:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/19\">",
"      Louis-Sylvestre C, Haddad B, Paniel BJ. Treatment of vaginal outflow tract obstruction in graft-versus-host reaction. Am J Obstet Gynecol 2003; 188:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/20\">",
"      Hirsch P, Leclerc M, Rybojad M, et al. Female genital chronic graft-versus-host disease: importance of early diagnosis to avoid severe complications. Transplantation 2012; 93:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/21\">",
"      Stratton P, Turner ML, Childs R, et al. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol 2007; 110:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/22\">",
"      Zantomio D, Grigg AP, MacGregor L, et al. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant 2006; 38:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/23\">",
"      Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/24\">",
"      Shulman HM, Sharma P, Amos D, et al. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 1988; 8:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/25\">",
"      Epstein O, Thomas HC, Sherlock S. Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease. Lancet 1980; 1:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/26\">",
"      Schubert MM, Sullivan KM. Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 1990; :135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/27\">",
"      Schubert MM, Sullivan KM, Morton TH, et al. Oral manifestations of chronic graft-v-host disease. Arch Intern Med 1984; 144:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/28\">",
"      McDonald GB, Sullivan KM, Plumley TF. Radiographic features of esophageal involvement in chronic graft-vs.-host disease. AJR Am J Roentgenol 1984; 142:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/29\">",
"      Cruz-Correa M, Poonawala A, Abraham SC, et al. Endoscopic findings predict the histologic diagnosis in gastrointestinal graft-versus-host disease. Endoscopy 2002; 34:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/30\">",
"      Snover DC, Weisdorf SA, Vercellotti GM, et al. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 1985; 16:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/31\">",
"      Hildebrandt GC, Fazekas T, Lawitschka A, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011; 46:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/32\">",
"      Song I, Yi CA, Han J, et al. CT findings of late-onset noninfectious pulmonary complications in patients with pathologically proven graft-versus-host disease after allogeneic stem cell transplant. AJR Am J Roentgenol 2012; 199:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/33\">",
"      Grauer O, Wolff D, Bertz H, et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain 2010; 133:2852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/34\">",
"      Parker P, Chao NJ, Ben-Ezra J, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore) 1996; 75:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/35\">",
"      Janin A, Socie G, Devergie A, et al. Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases. Ann Intern Med 1994; 120:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/36\">",
"      Oda K, Nakaseko C, Ozawa S, et al. Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT. Bone Marrow Transplant 2009; 43:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/37\">",
"      Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford) 2003; 42:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/38\">",
"      Marks C, Stadler M, H&auml;usermann P, et al. German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. Br J Dermatol 2011; 165:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/39\">",
"      Ahmad I, Labb&eacute; AC, Chagnon M, et al. Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/40\">",
"      Kuzmina Z, Eder S, B&ouml;hm A, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 2012; 26:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/41\">",
"      Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood 2005; 105:4885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/42\">",
"      Shimada M, Onizuka M, Machida S, et al. Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. Br J Haematol 2007; 139:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/43\">",
"      Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008; 111:3276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/44\">",
"      Kier P, Penner E, Bakos S, et al. Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transplant 1990; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/45\">",
"      Siegert W, Stemerowicz R, Hopf U. Antimitochondrial antibodies in patients with chronic graft-versus-host disease. Bone Marrow Transplant 1992; 10:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/46\">",
"      Witherspoon RP, Storb R, Ochs HD, et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981; 58:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/47\">",
"      Lum LG, Orcutt-Thordarson N, Seigneuret MC, Storb R. The regulation of Ig synthesis after marrow transplantation. IV. T4 and T8 subset function in patients with chronic graft-vs-host disease. J Immunol 1982; 129:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/48\">",
"      Elfenbein GJ, Anderson PN, Humphrey RL, et al. Immune system reconstitution following allogeneic bone marrow transplantation in man: a multiparameter analysis. Transplant Proc 1976; 8:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/49\">",
"      Perreault C, Giasson M, Gyger M, et al. Serum immunoglobulin levels following allogeneic bone marrow transplantation. Blut 1985; 51:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/50\">",
"      Witherspoon RP, Kopecky K, Storb RF, et al. Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. Transplantation 1982; 33:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/51\">",
"      Abedi MR, Hammarstr&ouml;m L, Ringd&eacute;n O, Smith CI. Development of IgA deficiency after bone marrow transplantation. The influence of acute and chronic graft-versus-host disease. Transplantation 1990; 50:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/52\">",
"      Reyes MG, Noronha P, Thomas W Jr, Heredia R. Myositis of chronic graft versus host disease. Neurology 1983; 33:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/53\">",
"      Smith CI, Aarli JA, Biberfeld P, et al. Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin. N Engl J Med 1983; 309:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/54\">",
"      Lin J, Markowitz GS, Nicolaides M, et al. Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation. Report of 2 cases and review of the literature. Am J Nephrol 2001; 21:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/55\">",
"      Barbara JA, Thomas AC, Smith PS, et al. Membranous nephropathy with graft-versus-host disease in a bone marrow transplant recipient. Clin Nephrol 1992; 37:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/56\">",
"      Srinivasan R, Balow JE, Sabnis S, et al. Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol 2005; 131:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/57\">",
"      Colombo AA, Rusconi C, Esposito C, et al. Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease. Transplantation 2006; 81:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/58\">",
"      Brukamp K, Doyle AM, Bloom RD, et al. Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease? Clin J Am Soc Nephrol 2006; 1:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/59\">",
"      Carpenter PA. How I conduct a comprehensive chronic graft-versus-host disease assessment. Blood 2011; 118:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/60\">",
"      Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/61\">",
"      Greinix HT, Loddenkemper C, Pavletic SZ, et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant 2011; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/62\">",
"      Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4 Suppl 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/63\">",
"      Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/64\">",
"      Chronic GVHD Consortium. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant 2011; 17:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/65\">",
"      Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011; 118:4242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/66\">",
"      Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011; 117:4651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/67\">",
"      Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011; 117:6714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/68\">",
"      Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/69\">",
"      Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003; 102:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/25/23962/abstract/70\">",
"      Kim ST, Jung CW, Lee J, et al. New clinical grading system for chronic GVHD predicts duration of systemic immunosuppressive treatment and GVHD-specific and overall survival. Bone Marrow Transplant 2007; 39:711.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3548 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23962=[""].join("\n");
var outline_f23_25_23962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25783453\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89544863\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL AND HISTOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6074138\">",
"      Distribution of disease and definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mucocutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6074276\">",
"      - Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6074386\">",
"      - Eyes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6074283\">",
"      - Hair and nails",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H978026\">",
"      - Genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6225168\">",
"      Musculoskeletal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6225507\">",
"      Hematopoietic and immune",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6225514\">",
"      - Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6225565\">",
"      - IgA deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H979753\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NIH consensus criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6074145\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS AND GRADING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H210172026\">",
"      NIH consensus criteria for GVHD severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H210172246\">",
"      CIBMTR chronic GVHD risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Johns Hopkins grading system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H979161\">",
"      Limited versus extensive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25783453\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3548\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3548|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/2/7209\" title=\"figure 1\">",
"      Organ scoring of chronic GVHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3548|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/46/5858\" title=\"picture 1\">",
"      Chronic GVHD - poikiloderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/2/34851\" title=\"picture 2\">",
"      Lichenoid chronic GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/44/19151\" title=\"picture 3\">",
"      Chronic GVHD - subcutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/2/4130\" title=\"picture 4\">",
"      Chronic GVHD - range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/63/4082\" title=\"picture 5\">",
"      Sclerotic chronic GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/37/27216\" title=\"picture 6\">",
"      Lichen sclerosus - trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/42/29345\" title=\"picture 7\">",
"      Chronic GVHD nail dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/50/18215\" title=\"picture 8\">",
"      Endoscopic staging upper GI-GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/6/17511\" title=\"picture 9\">",
"      Endoscopic staging lower GI-GVHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3548|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/15/21757\" title=\"table 1\">",
"      Features of chronic GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/16/38156\" title=\"table 2\">",
"      Cholestatic causes jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/58/39852\" title=\"table 3\">",
"      Dx intrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=related_link\">",
"      Causes of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=related_link\">",
"      Cutaneous manifestations of graft-versus-host disease (GVHD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8360?source=related_link\">",
"      Eosinophilic fasciitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_25_23963="Histologic clinical class idiopathic interstitial pneumonias";
var content_f23_25_23963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of idiopathic interstitial pneumonias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathologic pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic pulmonary fibrosis (IPF)",
"       </td>",
"       <td>",
"        Usual interstitial pneumonia (UIP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desquamative interstitial pneumonia (DIP)",
"       </td>",
"       <td>",
"        Desquamative interstitial pneumonia (DIP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory bronchiolitis interstitial lung disease (RBILD)",
"       </td>",
"       <td>",
"        Respiratory bronchiolitis (RB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute interstitial pneumonia (AIP)",
"       </td>",
"       <td>",
"        Diffuse alveolar damage (DAD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonspecific interstitial pneumonia (NSIP)",
"       </td>",
"       <td>",
"        Nonspecific interstitial pneumonia (NSIP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptogenic organizing pneumonia (COP)",
"       </td>",
"       <td>",
"        Organizing pneumonia (OP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoid interstitial pneumonia (LIP)",
"       </td>",
"       <td>",
"        Lymphoid interstitial pneumonia (LIP)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Resp Crit Care Med 2002; 165:277.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23963=[""].join("\n");
var outline_f23_25_23963=null;
var title_f23_25_23964="Sliding insulin scale for postpartum mgt of glucose levels";
var content_f23_25_23964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sliding insulin scale for postpartum management of glucose levels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Glucose values (mg/dL/mmol/L)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Insulin sensitive patients*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Insulin resistant patients*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        All other patients*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        AC",
"       </td>",
"       <td class=\"subtitle2\">",
"        HS",
"       </td>",
"       <td class=\"subtitle2\">",
"        AC",
"       </td>",
"       <td class=\"subtitle2\">",
"        HS",
"       </td>",
"       <td class=\"subtitle2\">",
"        AC",
"       </td>",
"       <td class=\"subtitle2\">",
"        HS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;150/8.3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        151-200/8.4-11.1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        201-250/11.2-13.8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        251-300/13.9-16.6",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        301-350/16.7-19.4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        351-400/19.5-22.2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AC: before meals; HS: bedtime.",
"     <br>",
"      * In this system, we assume that lean type 1 diabetes patients are likely to be insulin sensitive, while obese type 2 diabetes patients are likely to be insulin resistant. All other patients fall into the remaining group.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23964=[""].join("\n");
var outline_f23_25_23964=null;
var title_f23_25_23965="Drug regimens for tuberculosis";
var content_f23_25_23965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug regimens for active tuberculosis in adults caused by drug-susceptible organisms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Initial phase",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Continuation phase",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       <p>",
"        Range of total doses",
"       </p>",
"       <p>",
"        (minimal duration)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Rating*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Drugs",
"      </td>",
"      <td class=\"subtitle2\">",
"       Interval and doses&bull; (minimal duration)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Drugs",
"      </td>",
"      <td class=\"subtitle2\">",
"       Interval and doses&bull; &Delta; (minimal duration)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Regimen 1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"3\">",
"       <p>",
"        INH",
"       </p>",
"       <p>",
"        RIF",
"       </p>",
"       <p>",
"        PZA",
"       </p>",
"       <p>",
"        EMB",
"       </p>",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        Seven days per week for 56 doses (8 wk)",
"       </p>",
"       <p>",
"        or 5 d/wk for 40 doses (8 wk)&loz;",
"       </p>",
"      </td>",
"      <td>",
"       1a. INH/RIF",
"      </td>",
"      <td>",
"       <p>",
"        Seven days per week for 126 doses (18 wk)",
"       </p>",
"       <p>",
"        or 5 d/wk for 90 doses (18 wk)&loz;",
"       </p>",
"      </td>",
"      <td>",
"       182-130 (26 wk)",
"      </td>",
"      <td>",
"       A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1b. INH/RIF",
"      </td>",
"      <td>",
"       Twice weekly for 36 doses (18 wk)",
"      </td>",
"      <td>",
"       92-76 (26 wk)",
"      </td>",
"      <td>",
"       A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1c. INH/RPT&sect;",
"      </td>",
"      <td>",
"       Once weekly for 18 doses (18 wk)",
"      </td>",
"      <td>",
"       74-58 (26 wk)",
"      </td>",
"      <td>",
"       B",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Regimen 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       <p>",
"        INH",
"       </p>",
"       <p>",
"        RIF",
"       </p>",
"       <p>",
"        PZA",
"       </p>",
"       <p>",
"        EMB",
"       </p>",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        Seven days per week for 14 doses (2 wk), then twice weekly for 12 doses (6 wk) or",
"       </p>",
"       <p>",
"        5 d/wk for 10 doses (2 wk)&loz;, then twice weekly for 12 doses (6 wk)",
"       </p>",
"      </td>",
"      <td>",
"       2a. INH/RIF",
"      </td>",
"      <td>",
"       Twice weekly for 36 doses (18 wk)",
"      </td>",
"      <td>",
"       62-58 (26 wk)",
"      </td>",
"      <td>",
"       A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2b. INH/RPT&sect;",
"      </td>",
"      <td>",
"       Once weekly for 18 doses (18 wk)",
"      </td>",
"      <td>",
"       44-40",
"      </td>",
"      <td>",
"       B",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Regimen 3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        INH",
"       </p>",
"       <p>",
"        RIF",
"       </p>",
"       <p>",
"        PZA",
"       </p>",
"       <p>",
"        EMB",
"       </p>",
"      </td>",
"      <td>",
"       Three times weekly for 24 doses (8 wk)",
"      </td>",
"      <td>",
"       3a. INH/RIF",
"      </td>",
"      <td>",
"       Three times weekly for 54 doses (18 wk)",
"      </td>",
"      <td>",
"       78 (26 wk)",
"      </td>",
"      <td>",
"       B",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Regimen 4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       <p>",
"        INH",
"       </p>",
"       <p>",
"        RIF",
"       </p>",
"       <p>",
"        EMB",
"       </p>",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        Seven days per week for 56 doses (8 wk)",
"       </p>",
"       <p>",
"        or 5 d/wk for 40 doses (8 wk)&loz;",
"       </p>",
"      </td>",
"      <td>",
"       4a. INH/RIF",
"      </td>",
"      <td>",
"       <p>",
"        Seven days per week for 217 doses (31 wk)",
"       </p>",
"       <p>",
"        or 5 d/wk for 155 doses (31 wk)&loz;",
"       </p>",
"      </td>",
"      <td>",
"       273-195 (39 wk)",
"      </td>",
"      <td>",
"       C",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4b. INH/RIF",
"      </td>",
"      <td>",
"       Twice weekly for 62 doses (31 wk)",
"      </td>",
"      <td>",
"       118-102 (39 wk)",
"      </td>",
"      <td>",
"       C",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EMB: ethambutol; INH: isoniazid; PZA: pyrazinamide; RIF: rifampin; RPT: rifapentine.",
"     <br>",
"      * Definitions of ratings: A: preferred; B: acceptable alternative; C: offer when A and B cannot be given.",
"      <br>",
"       &bull; When DOT is used, drugs may be given 5 days/week and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicates this would be an effective practice.",
"       <br>",
"        &Delta; Patients with cavitation on initial chest radiograph and positive cultures at completion of 2 months of therapy should receive a 7-month (31-week; either 217 doses [daily] or 62 doses [twice weekly]) continuation phase.",
"        <br>",
"         &loz; Five-day-a-week administration is always given by DOT.",
"         <br>",
"          &sect; Options 1c and 2b should be used only in HIV-negative patients who have negative sputum smears at the time of completion of 2 months of therapy and who do not have cavitation on the initial chest radiograph (see text). For patients started on this regimen and found to have a positive culture from the two month specimen, treatment should be extended an extra three months.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Am J Respir Crit Care Med 2003; 167:603.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23965=[""].join("\n");
var outline_f23_25_23965=null;
var title_f23_25_23966="Immobile arm in children with neurologic deficits";
var content_f23_25_23966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F88518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F88518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Immobile arm in children with neurologic deficits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 276px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Erb or Klumpke palsy",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     In some patients with rapid return of normal function, the diagnosis of Todd paralysis may be made without neuroimaging, especially those with a history of prior episodes.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23966=[""].join("\n");
var outline_f23_25_23966=null;
var title_f23_25_23967="Pancoast tumor MRI II";
var content_f23_25_23967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uninvolved right lung in a patient with a left Pancoast tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A section from the uninvolved right side of the neck is included for comparison with the previous figure. There is no invasion into the base of the neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_25_23967=[""].join("\n");
var outline_f23_25_23967=null;
